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Lung surfactants (LSs) are a complex mixture of lipids and proteins that are found in the 
alveolar lining of the lungs. Their primary objective lies in lowering the surface tension of 
the aqueous layer on which they reside. By doing so, LSs reduce the energy involved in 
breathing, and any loss/ dysfunction of the surfactants can cause fatal respiratory 
complications. Successful treatment methods require a thorough understanding of the 
biophysical properties of the LSs, and their interaction with any material that may come 
in contact. This dissertation aims at evaluating the interaction of the different lipids found 
in the surfactant pool with such plausible candidates at the air-water interface. 
Engineered carbon nanodiamonds (ECNs) is selected because of their potential in 
becoming a candidate for drug delivery through the respiratory tract. Therefore, it is 
necessary to evaluate any possible toxic outcome from ECNs. Here, we observe that 
both the lipid headgroup charge and the tail saturation impact the biophysical properties 
of the monolayer. We also evaluate the impact of the protein, Mini-B, which is a synthetic 
analog of the native surfactant protein, SP-B, on the biophysical properties of the LSs. 
Mini-B is a suitable candidate for surfactant replacement therapy (SRT), which is 
associated with lung diseases. Thus, Mini-B needs a thorough biophysical analysis. 
Lastly, we observe the effectiveness of Mini-B in countering the deleterious effects of 
cholesterol. Cholesterol is found in the native mixture and helps in fluidizing the 
monolayer. However, cholesterol has been reported to have some harmful impact on the 
LSs. Thus, it is a highly disputed component in SRT, with some formulations removing 
cholesterol from their product. We observe that 1 to 5 wt.% of Mini-B can counter the 
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1.1.Origin of lung surfactants:  
Lung surfactants [LSs] are a complex mixture of lipids and proteins. 
Through the process of exocytosis of vesicles, called Lamellar Bodies [LBs], LSs 
are released into the alveolar space from Alveolar Type II [AT II] cells [1, 2]. Prior 
to birth, a glycogen pool acts as the source of carbon for the LSs, however, after 
birth the phospholipids are synthesized in the endoplasmic reticulum. The 
various components of the surfactants are then transported to the lamellar bodies 
[LBs], which act as a storage location for the surfactants. In addition to the 
phospholipids, two major surfactant proteins are also present in the LBs. These 
surfactants, namely, SP-B and SP-C, are synthesized in the endoplasmic 
reticulum, and then via the Golgi apparatus, transported to the LBs. LBs are 
bound by a limiting membrane that fuses with the plasma membrane. Eventually, 
from the LBs, the LSs are released into the extracellular region [3, 4]. However, 
not all the components of the surfactants are present in the LBs. Surfactant 
proteins, namely SP-A and SP-D are secreted independently. Once the 
surfactants are released in the extracellular region, the complex components give 
rise to three dimensional, lattice-like macromolecular aggregates, called Tubular 
Myelin [TM], in the alveolar lining fluid [ALF]. The ALF is thin and continuous over 
the surface of the alveoli, ranging between 0.1 µm to several µms in thickness 
[5]. The lipophilic nature of the surfactants combined with contribution from SP-A 
and divalent ions (Ca2+) help in the formation of TM [6, 7]. However, TM is not 
the only structure that appears in the ALF. Several other microstructures such as 
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small vesicles [SVs] are also present in the alveolar lining fluid [8]. From these 
aggregates the surfactants finally make their way to the surface of the liquid 
lining.  
 Once reaching the surface of the ALF, the surfactants form a film. The 
primary function of this film is to lower the surface tension. The molecules at the 
surface face forces that are not balanced. The attractive forces at the interface 
try to minimize the area covered. While exhaling, these forces can be strong 
enough to collapse the alveoli, which in turn reduces the area for gas exchange. 
The surfactants displace the water molecules at the interface, which reduces the 
attractive forces acting at the surface.  This result in the lowering of surface 
tension, thereby, avoiding the collapse of the alveoli [9]. Therefore, the role of 
surfactant is paramount in the proper physiological functioning of the lungs, and 
any lack or dysfunction of the surfactants results in a multitude of diseases. Most 
commonly, neonatal respiratory distress syndrome [NRDS] and hyaline 
membrane disease has been linked with lung surfactant disorder [10].  
Additionally, many obstructive pulmonary diseases have been linked with lung 
surfactant disorder [11]. The list includes asthma, chronic obstructive pulmonary 
disorder [COPD], cystic fibrosis, and pneumonia. Furthermore, interstitial lung 
diseases such as idiopathic pulmonary fibrosis, sarcoidosis, pulmonary alveolar 
proteinosis, and hypersensitivity pneumonitis have also been associated with 
surfactant disorders.  Thus studying the biophysical properties of the surfactants 
is of utmost importance. In fact, surfactant replacement therapy has been 
clinically successful in the case of newborn babies suffering from respiratory 
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distress syndrome [12]. However, most clinically approved surfactants at present 
are animal derived, and these natural surfactants are given preference over the 
synthetic ones. Studies have shown a marginal decrease in the risk of mortality 
with animal derived surfactants but at the same time, an increase in intra 
ventricular hemorrhage was reported with these surfactants [13]. Thus, further 
research is needed to come up with effective synthetic surfactants. More 
compositions need to be tested, and their biophysical properties and molecular 
interactions at the interface must be evaluated.  
 
1.2 Composition of Natural Lung Surfactants:  
Natural lung surfactants primarily consist of lipids [14]. Among the different 
components of lipids, the phospholipids form the primary constituent. Trace 
amounts of phosphatidylinositol, phosphatidylserine and plasmalogen analog of 
phosphatidylcholine are found in the surfactants. However, the bulk of the 
phospholipids are made up of Phosphatidylcholine, of which 
dipalmitoylphosphatidylcholine, DPPC accounts for 41-70% of the 
phosphatidylcholine. Furthermore, 10 mol% of phosphatidylglycerol forms 
another significant component of the surfactants. Other than phospholipids, 
neutral lipids also are a part of the surfactant mixture, particularly, cholesterol. 
Cholesterol makes up for 8 weight % of the lung surfactants. Lastly, surfactant 
proteins contribute to about 10% of the mixture. SP-A and SP-D comprises of the 
majority of the surfactant proteins, however, even at lower concentrations, SP-B 
and SP-C contributes significantly to the proper physiological functioning of the 
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Fig 1. Composition of the bovine lung: The saturated DPPC, at 36%, forms the 
major component of the lung surfactants. The unsaturated PC group of 
phospholipids comes in second at 33%. Thus, PC headgroup comprises of most 
of the surfactant pool. The PG headgroup contributes to 10% of the total 
composition. This includes both saturated and unsaturated PG lipids. 
Phosphatidylinositol, PI, lipids form around 1.5% whereas, cholesterol stands 
around 2.5%. The minor components consist of phosphatidylethanolamine, PE, 





1.3 Function of Natural Lung Surfactants:  
The main objective of the surfactants is to reduce the surface tension of 
the alveolar fluid lining. Surfactant vesicles in the alveolar fluid lining adsorb 
highly rapidly to the surface, and during exhalation, the surfactants are capable 
of lowering the value of surface tension to near zero values [16]. However, lung 
surfactants also promote gas exchange and alveolar stability among other 















Table 1: The biophysical functions of lung surfactants have been taken from ref 
[10], lists the different physiological functions of the lung surfactants.  
 
Other than the biophysical functions listed above, the surfactants also serve an 
important role in defending against foreign invasions. Specifically, the proteins 
SP-A and SP-D help in opsonizing microorganisms for their effective removal 
through phagocytosis. Thus, SP-A and SP-D help modulate is involved with 
modulating phagocytosis, oxidative bursts of macrophages and chemotaxis. 
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Additionally, SP-A and SP-D also bind and capture bacterial toxin for their swift 
removal. Furthermore, the phospholipids of the lung surfactants also inhibit the 
release of endotoxin-stimulated cytokine from macrophages [10]. Therefore, lung 
surfactants play a vital role in the proper functioning of the lungs along with 
carrying out immunological tasks.  
 
1.4. Function of individual components: 
1.4.1 Phospholipids: The saturated phospholipid, DPPC, is the only component 
in the surfactant pool that can lower the surface tension to near zero values at 
the air/water interface of the alveoli at the end of each respiratory cycle [17]. Fig 
2 shows the molecular structure of DPPC.  
 
Fig 2.  The image represents the molecular make up of two major components of 
the lung surfactants, (A) DPPC and (B) POPG. (Source: Avanti Polar Lipids) 
 
The two 16 carbon acyl chains in DPPC are devoid of any unsaturation. 
Therefore, when compressed, the acyl chains can line up perfectly and form a 
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highly packed monolayer. The ability of DPPC to pack tightly allows it to remain 
at the interface at high compression, which eventually lowers the surface tension. 
Furthermore, in vitro studies suggest two theories for DPPC build-up at the 
surface. One is the addition of new DPPC into the monolayer and the other one 
is the squeeze-out of unsaturated lipids from the surface and the subsequent 
enrichment of the monolayer with DPPC [18]. A modified squeeze out method 
has also been proposed where the formation of multiple layers was observed 
with Langmuir studies [19]. Here, the monolayer, while getting enriched with 
saturated phospholipids, removes the unsaturated components from the surface. 
These unsaturated lipids then form multilayered stacks that remain associated 
with the surface because of the surfactant proteins. Although DPPC serves the 
primary purpose of lowering the surface tension, it has been observed that 
vesicles of DPPC films form monolayers extremely slowly at temperatures lower 
than its gel-to-fluid phase transition temperature of 41oC. Therefore, at body 
temperature, DPPC is too rigid to be able to adsorb rapidly to the interface. 
Additionally, DPPC on it’s own is also incapable spreading quickly on the 
surface. These disadvantages associated with DPPC gives rise to the necessity 
of other components that are more fluid than the saturated ones. In this regard, 
the acidic phospholipids play an important part. As discussed earlier, unsaturated 
PG and PI also contribute to the mixture, and a combination of the unsaturated 
phospholipids along with DPPC enhances the adsorption and respreading of 
material at the interface. Furthermore, the acidic unsaturated components can 
also interact with surfactant proteins, which further improves the properties of the 
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surfactants. Lower quantities of PG lipids decrease the biophysical activities of 
the surfactants, and have also been linked with acute respiratory distress 
syndrome. However, the unsaturation in the acyl chain, as can be seen in Fig 2B, 
prevents these molecules from packing tightly at the interface when compressed, 
and usually, they collapse within a surface pressure of 50 mN/m. Other than the 
PC, PG and PI lipids, there are some minor constituents in the native surfactant 
mixture. But it is unlikely that these molecules provide a significant contribution 
towards the biophysical activity of the mixture.  
1.4.2 Neutral Lipids: Finally, some neutral lipids, most notably cholesterol, is 
also present in the native mixture. Cholesterol primarily increases the fluidity of 
the mixture. Low quantities of cholesterol have been shown to be effective in 
surfactant mixtures. However, the presence of a high concentration of cholesterol 
fails to lower the surface tension to zero [20-24]. The biophysical activity of the 
surfactants is lowered because cholesterol cannot be squeezed out of the 
monolayer with ease [25]. Therefore, the monolayer is no longer enriched in 
DPPC, making it impossible to reach near zero surface tension. Furthermore, in 
vivo studies have also shown the presence of elevated quantities of cholesterol 
in the case of ventilator-induced lung injury. This form of injury also leads to a 
reduction in the biophysical activity of the lung surfactants [26]. However, as 
mentioned earlier, native surfactant contains cholesterol. Additionally, it has been 
observed that small quantities of cholesterol can improve the biophysical 
properties of the lung surfactants [27]. Essentially, small quantities of cholesterol 
are capable of lowering the viscosity of the surfactants, thus increasing the 
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spreadability of the surfactants at the interface. Additionally, studies with captive 
bubble surfactometer have shown that cholesterol has negligible impact on BLES 
[28]. Strikingly, inconsistency in the formulation of medicinal surfactants can be 
observed. Some formulations used in surfactant replacement therapy consist of 
cholesterol, while others actively remove the cholesterol component.  Therefore, 
there is little consensus in the composition of the synthetic or animal derived 
surfactants. In practice, commercial surfactants like, Survanta ® (bovine lung 
mince) has less than 0.2% cholesterol, whereas, Curosurf ® (Porcine lung 
mince) has no cholesterol at all. The same is the case for entirely synthetic 
compositions where no cholesterol is added to the mixture. On the contrary, 
Infasurf ® (calf lung lavage), BLES ® (bovine lung lavage) and BNS (Bovine 
Lung Lavage) contain up to 8% cholesterol [29]. Therefore, the purpose and use 
of cholesterol in the formulations for replacement therapy is extensively debated.   
1.4.3 Surfactant Proteins: The four surfactant proteins plays specific functions 
related to the biophysical activity of the surfactants and the promotion of immune 
response. The surfactant proteins can be divided into two categories, namely, the 
hydrophobic group, and the other one being the hydrophilic group.  
1.4.3.1 Hydrophobic Proteins: The surfactant proteins SP-B and SP-C are the 
two hydrophobic proteins found in the surfactant pool. The 17 kDa SP-B contains 
79-amino acid in its molecular construct. This amphipathic peptide is prepared in 
the type II epithelial cells [30, 31]. It belongs to the sphingolipid activator saposin 
family of proteins. SP-B has a longer, 381 amino acids precursor. However, it 
goes through a proteolytic cleavage of the N- and C- terminals to get into the final 
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sequence. The mature SP-B is highly cationic with a net positive charge of +7. 
Additionally, dimerization of the monomeric form occurs with the formation of 
intermolecular disulfide bond at Cys48. After the completion of the cleavage of 
the proprotein in the type II epithelial cell, the dimerization takes place. In native 
surfactants, SP-B is present in quantities less than 1.5% of the total weight. 
However, even at a small concentration, SP-B is capable of significantly 
enhancing the properties of the native surfactants. In fact, absence of SP-B has 
been shown to be severely detrimental [32-35]. On the other hand, the SP-C is a 
smaller peptide with a molecular mass of 4.2 kDa and containing 35 amino acid 
residue [36]. SP-C is also a positively charged peptide alongside having over 
70% non-polar residues, making it highly hydrophobic. Both SP-B and SP-C 
have been intensively studied to find out their significance in the surfactant 
mixture. SP-B and SP-C help with lipid insertion into the monolayer [37]. 
Furthermore, it has also been shown that at low surface pressures, SP-B 
fluidizes the monolayer, whereas at high surface pressures, SP-C increases the 
compressibility of the monolayers [38]. Additionally, because they promote the 
insertion of lipid molecules into the air/water interface, they help with lowering the 
surface tension and prevent the insertion of serum into the monolayer. Overall, 
SP-B helps with the reconstitution of the tubular myelin, enhances adsorption of 
the phospholipid to the interface and helps with respiratory function. On the other 
hand, SP-C aids in stabilizing surface-associated surfactant reservoirs. SP-C 
also promotes the adsorption of phospholipids to the air/water interface [39]. The 





Interacts selectively with the PG headgroup of phospholipid bilayers 
Promotes the aggregation of phospholipids 
Also interacts with the superficial region of the bilayer 
Helps with stabilizing phospholipid monolayers 
Promotes squeeze out  
Promotes the exchange of phospholipids between vesicles and bilayers 
Helps in incorporating phospholipid molecules into the air/water interface 
SP-C 
 Interacts with bilayers 
Helps with squeeze out 
Helps in creating three-dimensional structures 
Helps in respreading of films 
  
Table 2: The table summarizes the functions of SP-B and SP-C in the surfactant 
mixture [39].  
1.4.3.2. Hydrophilic Proteins: SP-A and SP-D are two hydrophilic members of 
the surfactant pool, with significantly larger size than that of SP-B and SP-C [40]. 
SP-A is a 630 kDa protein, whereas SP-D is a 520 kDa protein. Both SP-A and 
SP-D have been attributed with immunogenic functions. It has been shown to 
have anti-viral, anti-bacterial, anti-fungal properties among others.   
	 13	
1.4.3.3. Synthetic Proteins: First generation synthetic medicinal surfactants 
composed only of lipids. Alec, a mixture of DPPC along with egg PG, and 
Exosurf, a mixture of DPPC with hexadecanol and tyloxapol, were two synthetic 
mixtures devoid of any surfactant protein [41]. However, they found little clinical 
success. Thus, second generation medicinal surfactants have focused on 
preparing alternatives that contain synthetic analogs of SP-B and SP-C. Surfaxin 
and Venticute are two such examples, which have employed synthetic analog of 
SP-B, KL4 (Surfaxin) and recombinant human surfactant protein C, rhSP-C 
(Venticute). Truncated SP-B mimics with 1-25 amino acid residues, SP-B1-25, and 
49-66 amino acid residues, SP-B49-66, have also shown potency similar to that of 
their native parent protein [42, 43]. Mini-B is one such synthetic alternative that 
has been biophysically characterized in this work.  
Mini-B is a synthetic analog of SP-B containing 34 amino acid residue 
[44]. It is based on the predicted N- and C- terminals of SP-B. Similar to SP-B, 
Mini-B has a charge of +7. Containing four of the six conserved cysteines, which 
define the saposin fold, Mini-B is capable of forming disulfide bridge, C1-C33 and 
C4-27, between the two helices when oxidized. The amino acid sequence of 
Mini-B is as follows: -CWLCRALIKRIQAMIPKGGRMLPQL VCRLVLRCS, and it 
is synthesized by solid phase chemical synthesis via O-
fluorenylmethyloxycarbonyl (Fmoc) chemistry with partial 15N-labeling. The 
disulfide linkages are synthesized by the selective deprotection of the cysteine 
residues at C1 and C33 through trityl side-chain protecting protocol. Finally, air-
mediated oxidation of Mini-B forms the disulfide links at the desired location. 
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Mini-B is also effective in mimicking the in vitro and in vivo characteristics of SP-
B. It has been shown that the oxidized form of Mini-B containing the disulfide 
linkage is more potent at reducing surface tension than the reduced counterpart 
[45]. Furthermore, we had also shown the capability of Mini-B to counter the 
deleterious effects of cholesterol [46], which forms part of the current thesis.    
1.5. Impairment of lung surfactant activity:  
Pulmonary immaturity in the case of prematurely born infants leads to an 
absence of lung surfactants. This is a fatal condition, which needs an immediate 
clinical response. However, lung immaturity is not the only source of surfactant 
impairment [47]. A loss in the activity of lung surfactants may occur at any age 
because of an injury to the type II alveolar cells. Furthermore, the presence of 
inhibitors may also cause abnormalities in the lungs. These abnormalities then 
trigger an increase in the surface tension of the aqueous-lining in the alveoli, 
which in turn, severely impacts the breathing process. Degradation of the 
components may also cause similar irregularities. Degrading agents like 
phospholipases, released during pulmonary inflammation, may trigger respiratory 
distresses. Thus, the properties of the individual components along with their 
interaction with foreign agents must be thoroughly studied to devise necessary 
medical intervention.  
 Among the different components in the surfactant pool, cholesterol 
is a disputed one because of its potential detrimental impact on the biophysical 
properties of the lung surfactants [48, 49].  The function of cholesterol in the 
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native surfactant mixture is still relatively unknown. Even at low concentrations, 
cholesterol is capable of altering the morphology and dynamics of phospholipid 
monolayers [27]. Furthermore, elevated concentrations of cholesterol have been 
found in lung diseases [26, 50]. Therefore, cholesterol is removed from most 
commercial surfactant mixtures. However, some studies have indicated that at 
physiological concentrations, cholesterol has less impact compared to that at 
elevated conditions [20, 23, 24]. Additionally, native surfactant mixture contains 
cholesterol and is capable of lowering surface tension to near zero values. 
Moreover, cholesterol is capable of lowering the phase transition temperature of 
the lipids [28]. Highly ordered, rigid lipid in the gel phase transitions to a more 
fluid, liquid-crystalline phase in the presence of cholesterol, meaning, cholesterol 
enhances the fluidity of the lung surfactant mixture, which in turn improves the 
spreadability of the surfactants [51]. Thus, a balanced lung surfactant mixture is 
needed, which can lower surface tension to near zero and at the same time be 
fluid enough to spread rapidly. Cholesterol can therefore be a critical component 
in surfactant-mediated intervention. To counter the deleterious effects of 
cholesterol, SP-A has been used in the past [52]. Additionally, the protein SP-C 
has also been shown to counter the negative effects of cholesterol [53]. In our 
work [46], we investigated the role of the synthetic protein, Mini-B, in countering 
the adverse impact of cholesterol on the biophysical properties of the surfactant 
monolayer.  
Another component that may alter the functions of lung surfactants are 
foreign particles that are small enough to reach the inner linings of the alveoli. 
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Once reaching the alveoli, these nano-sized particles encounter the lung 
surfactants, which act as a line of defense against such particles. However, there 
are cases where nanoparticles maybe added to the lungs as a means of drug 
delivery. Artificially inserted or not, the toxicity of these particles must be 
evaluated, and any material that can adversely impact the functioning of the 
lungs must be discarded. The following section briefly introduces the use of 
nanoparticles and highlights the necessity to evaluate the potential toxic behavior 
of such particles. 
Nanotechnology, which involves the formulation, characterization and 
application of nano-sized solid particles, has been gaining ground rapidly over 
the past several decades. The nano-scale size of these particles makes their 
properties different from that of their bulk counterpart. These properties provide 
some unique advantages to the nanoparticles. They have a large ratio of surface 
area to volume. Additionally, the surface properties of these particles can be 
easily modified. Furthermore, related to therapy and diagnostics, the shape and 
the size of these particles allow them to reach locations that are otherwise 
impregnable. Thus, nanoparticles are regularly used in medicine, cosmetics, 
solar cells, agriculture and food sector, water treatment, oil and gas industry, 
textile industry, construction industry to name a few of the sectors [54-69]. From 
brake pads in vehicles to manufacturing plants, nanoparticles are widely present 
[70, 71]. Additionally, engineered nanoparticles are being constantly used in a 
variety of consumer products [72]. Of the various nanoparticles, carbon 
nanodiamonds is an emerging type of nanomaterial. The detonation synthesis of 
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nanodiamonds was discovered in 1963 but over the last two decades, multiple 
synthesis techniques have been optimized to provide the nanodiamonds with 
unique physical, chemical, and biological properties [73, 74].  These particles 
have found application in both diagnosis and therapeutics. However, the increase 
in use has also led to an increase in the exposure of these particles. As a 
consequence, there are multiple routes of entry for the nanoparticles, and owing 
to both systemic and local advantage related to drug delivery, the respiratory 
tract is one favorable port of insertion [75]. On their own, lung surfactants provide 
hydrophobic regions that can host therapeutic molecules and poorly soluble 
drugs, which can treat both respiratory and systemic diseases [76, 77]. Thus, the 
surfactants can act as a simple excipient for the drug when considering systemic 
diseases, and in the case of local respiratory illness, the surfactants can act as a 
therapeutic agent along with being carriers. However, the combination of 
surfactants with nanoparticles has also been considered for the purpose of drug 
delivery. Recently, a combination of siRNA loaded with dextran nanogel and an 
outer nano-composite was shown to be an effective method for delivering siRNA 
[78]. Thus, it is of utmost importance to assess the interaction of nanoparticles 
with lung surfactants so that their combination can be used as a carrier for drug 
molecules.  
Even though there are mechanical barriers like mucociliary apparatus and 
dendritic cells that capture larger particles [79], small enough materials are 
capable of inserting themselves into the alveoli through gravitational 
sedimentation, inertial impaction, interception and diffusion [80]. Thus, the size of 
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the particles plays a pivotal role in the location of deposition. The larger particles 
tend to get deposited in the upper layers of the respiratory canal, whereas the 
smaller ones are capable of reaching the alveoli. It has been reported that 
particles ranging within 100 to 200 nm in size have an approximately 15% 
likelihood to be deposited in the alveoli of the lungs [81]. Smaller particles that 
are around 20 nm in size have an even higher probability of reaching the alveoli. 
Furthermore, these particles may stay in the lungs for 700 days. Therefore, these 
particles may pose a threat to the proper functioning of the lungs. Moreover, the 
lung surfactants come in contact with the particles that reach the alveoli. 
Therefore, the surfactants form a barrier of resistance against both the unwanted 
and the medicinal nanomaterial. Furthermore, the behavior of the material in their 
nano form can be very different from their microform. For example, TiO2 
nanoparticles inhibited the biophysical function of surfactants as a function of 
concentration, but the micro-particles of TiO2 didn’t have the same effect [82]. As 
a result, it is necessary to monitor the possible toxic impact of the nanoparticles 
on the lung surfactants. Over the last several years, studies have focused on the 
biophysical interaction of lung surfactants with metallic and polymeric 
nanomaterial varying in size, composition, modifications in surface chemistry and 
surface potential. However, the results have been contradictory, and thus, 
making it even more necessary to continue investigating the nature of the 
interaction.  
 Fan et al. showed that even small concentrations of Hydroxyapatite 
nanoparticles can hinder the biophysical function of lung surfactants [83]. Here, a 
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progressive decay in the surface tension lowering capability of Infasurf was 
observed with time when 1 wt.% Hydroxyapatite nanoparticle was added. In two 
separate studies, Guzman et al. showed the impact of silica nanoparticles on the 
phase behavior of different model lung surfactant system [84, 85]. Valle et al 
suggested that hydrophobicity of polymeric nanoparticles plays a role when 
interacting with infasurf [86]. Increase in the hydrophobicity of the nanoparticles 
showed an increased deterioration in the biophysical properties of the 
nanoparticles. Furthermore, Harishchandra et al. showed the impact of 
organosiloxane nanoparticles on model lung surfactant systems [87]. Here, the 
nanoparticles caused a notable change in the phase behavior of the lung 
surfactants. Additionally, the lipid domain structure at the interface was also 
impacted by the nanoparticles. However, the damage to the biophysical 
properties of the surfactants was dependent on the concentration of the 
nanoparticle. Another study by Beck-Broichsitter et al. demonstrated the impact 
of polymeric nanoparticles on lung surfactant mixtures [88].  Higher concentration 
of the nanoparticles deteriorated the biophysical properties of the surfactants.   
The type of surfactant also impacted the biophysical behavior. This was 
previously observed by the same group, where only negatively charged 
polymeric nanoparticles notably deteriorated the biophysical properties of the 
surfactants [89]. Impact of metallic nanoparticles has also been investigated [82, 
90, 91]. In the case of gold nanoparticles, samples containing even less than 1 
wt.% of gold drastically inhibited the biophysical function of DPPC/POPG/SP-B 
monolayers [90]. But, the study by Tatur et al. displays that 0.2 mol% of the 
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hexadecanethiolate-capped gold nanoparticles didn’t have any effect on the 
surface tension lowering capability of DPPC but notably modified the lipid 
domains at the interface [91]. Even 16 wt.% of the nanoparticle had no effect on 
the clinical surfactant, Survanta. Survanta is a more complex lipid system than 
DPPC. Thus, there were discrepancies in the behavior of the same set of 
nanoparticles in the presence of different phospholipid systems. Studies so far 
focused on the properties of the nanoparticles like surface charge, size, shape, 
and type, but the difference in the behavior led us to investigate the interaction of 
engineered carbon nanodiamond [ECN] in the presence of different model lung 
surfactant systems [92].  
1.6. Thesis organization: 
The primary theme of the thesis is to evaluate the role of the 
phospholipids when interacting with other components that can come in contact 
with lung surfactants. Often times, the contribution of the phospholipids is 
neglected, having the focus predominantly on the foreign agents. However, the 
role of the phospholipids, and the overall composition, should not be neglected 
when determining the effectiveness of the surfactants in the presence of the 
foreign components. Furthermore, the knowledge from this thesis can be 
extended to lipid systems outside that of the lungs. For instance, the behavior of 
the engineered carbon nanodiamonds is dependent on the lipid mixture to which 
they are introduced. Therefore, even though these particles aren’t toxic to certain 
compositions in moderate quantities, they can be detrimental to some other 
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compositions. So, the route of entry of these particles has a notable impact on 
their behavior. The following section outlines the topics to be discussed in this 
dissertation.   
 Chapter 2 focuses on the impact of cholesterol on a model lung 
surfactant mixture. Furthermore, the synthetic protein, Mini-B, has been applied 
to counter the deleterious effects of cholesterol. Here, emphasis has been placed 
on two biophysical functions of the surfactants. The ability of the surfactants to 
lower surface tension to near zero values is the primary objective, whereas, the 
ability of the surfactants to readsorb and retain material at the interface after 
each cycle of compression and expansion is the second objective. Based on the 
performance of the compositions, the concentration of the mixture has been 
optimized. Smaller quantities of cholesterol can have a positive role in fluidizing 
the monolayer. We observe that 1% to 5% of Mini-B is capable of countering the 
deleterious effect of smaller concentrations of cholesterol. Increasing the 
concentration, however, still proves to be malicious for the surfactant mixture. 
 Chapter 3, on the other hand, discusses the impact of ECN on the 
biophysical properties of the lung surfactant monolayers. We primarily focus on 
the phospholipid composition when interacting with the ECN. Model mixtures 
containing two phospholipids have been studied in this chapter. Disaturated 
phosphatidylcholine has been kept constant for all the mixtures tested. The 
second phospholipid has been altered to modify the behavior of the monolayers. 
Altering the lipid headgroup charge and the lipid tail saturation also makes an 
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impact on the way the monolayers behave in the presence of ECN. The most 
profound negative influence is seen with mixtures that contain the neutral, mono-
unsaturated phosphatidylcholine. On the other hand, negatively charged 
disaturated phosphatidylglycerol shows favorable properties in the presence of 
ECN. The chapter also concludes that the anionic lipids are better suited to 
interact with ECN than their zwitterionic counterpart.  
Chapter 4 investigates the role of the phospholipid composition when 
interacting with the synthetic protein, Mini-B.  Here too, lowering of surface 
tension as well as the ability to readsorb and retain material at the surface has 
been considered as the key properties of the surfactants. We observed that a 
zwitterionic mixture with 5% Mini-B has the best response. Furthermore, we 
speculate that the vesicles formed in the case of the zwitterionic mixture get 
reincorporated into the interface. Lastly, we believe that the location of insertion 
of the protein into the interface plays a part in modifying the behavior of the 
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Lung surfactant [LS], produced by Type II epithelial cells, is a complex 
mixture of lipids and proteins present primarily in the alveolar lining of the lungs 
[1, 2]. LS help in lowering surface tension at the air-water interface with 
expiration, thereby reducing the energy needed for breathing and improving lung 
compliance [3, 4]. They also form a line of defense against any foreign particle 
that is small enough to make its way through the air canal [5]. It has been firmly 
established that there is a lack of LS in cases of Neonatal Respiratory Distress 
Syndrome [NRDS] occurring in infants [6]. Currently NRDS is treated with a high 
success by using exogenous surfactant, referred to as Surfactant Replacement 
Therapy (SRT) [7].  In comparison to NRDS, a dysfunction/ impairment of the 
surfactant may lead to Acute Respiratory Distress Syndrome (ARDS)/ Acute 
Lung Injury (ALI). Each year, a staggering 50,000-190,000 case of ALI/ARDS are 
reported in USA itself [8]. While SRT has also been proposed for treating this 
condition as well, the success of SRT is currently debated, possibly because of a 
lack of complete understanding of the biophysical interactions between different 
LS components [9]. Lack of complete understanding of the biophysical role of the 
different constituents in combination has resulted in a lack of consensus on the 
composition of lung surfactants used in SRT, and forms the main motivation of 
this work.  
Although native surfactants differ by species in their detailed composition, 
almost all contain about 90% by weight lipid and 10 wt. % of the surfactant 
specific proteins SP-A, SP-B, SP-C and SP-D [10, 11]. The dominant 
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phospholipid component is disaturated dipalmitoylphosphatidylcholine (DPPC, 
30-70%), along with some unsaturated phosphatidylcholine (PC, 25-35%), 
anionic phospholipids like phosphatidylglycerol (PG), saturated fatty acids like 
palmitic acid, neutral lipids like cholesterol as well as minor fractions of 
phosphatidylethanolamine (PE) and sphingomyelin [12-14]. Although less in 
quantity, surfactant proteins play a crucial part. The hydrophobic SPB and SPC 
are involved in enhancing adsorption of LS to the air-water interface, whereas, 
the hydrophilic SPA and SPD mainly play a part in immune response [15].  
Among the different constituents, the presence of cholesterol in SRT is 
highly disputed, primarily because its biophysical function in the proper 
functioning of the lung surfactant remains mostly unknown. Early experimental 
studies using Langmuir troughs and pulsating bubble surfactometer suggested 
that any amount of cholesterol is detrimental to the proper functioning of the lung, 
since the ability of the lung surfactant to reach a low surface tension (16-19) was 
inhibited in most of these studies. Cholesterol changes the morphology of DPPC 
domains even at low concentrations, which in turn can alter the surface tension 
lowering ability of DPPC [20].  
On the other hand, it is important to note that cholesterol forms the major 
neutral lipid component of endogenous lung surfactants (3-10 wt. %), yet near 
zero surface tensions have been measured in the lung(21), suggesting that 
physiological amounts of cholesterol do not interfere with the proper functioning 
of the lung. Lessons learned from evolutionary studies on mammalian lung show 
that high amounts of cholesterol are present in more primitive animals with sac-
	 38	
like lungs(22). The cholesterol content has been found to be 1.5 fold higher in 
hetero-thermic animals undergoing torpor(22). Kim et al showed that even small 
amounts (1 wt. %) can alter the surface viscosity of DPPC films, suggesting that 
addition of cholesterol to LS mixtures can be beneficial during intra-tracheal 
delivery of LS and enhance efficient spreading of synthetic LS, once it adsorbs to 
the interface. Interestingly,  Gunasekara et al., found that physiological amount of 
cholesterol has no effect on the surface activity of a natural surfactant BLES 
(Bovine Lipid Extract Surfactant) and only concentrations as high as 20% by 
weight, imposed harmful effects on the function of this natural LS [23]. This 
suggests the highly plausible explanation that minor components in native LS 
mixtures can counter some of the deleterious effects of cholesterol that was 
observed for early studies. Therefore, in order to use cholesterol in the 
replacement mixtures, any deleterious effects must be countered with other 
components. For example, Gomez-Gil et al. showed that surfactant protein SP-C 
can counter the deleterious effects of cholesterol, if used in the right proportions, 
suggesting that controlled amounts of cholesterol and proteins should be 
considered while developing future surfactants.  
SP-B is the only one among the four surfactant proteins that is essential 
for effective breathing. Therefore, in this paper, we focus on developing a 
biophysical understanding of protein interactions with the neutral lipid 
composition of the lung surfactant. Specifically, we report on biophysical 
properties of DPPC:POPG films containing different amounts of cholesterol, in 
the absence or presence of 1, 2.5 or 5 wt. % Mini-B.  Mini-B, a synthetic analog 
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of the surfactant protein SP-B, is a 34 amino acid residue of the full length native 
protein with enhanced in vivo and in vitro surfactant properties, where the 
predicted helices of the N and C terminals of the native protein are ether linked 
[24, 25], while maintaining the net charge (+7) of the native protein [26]. Mini-B 
can also aid an artificial phospholipase-resistant surfactant, diether 
phosphonolipid (DEPN) in lowering surface tension efficiently [27], with possible 
application in treating ALI/ARDS. Since an elevated amount of cholesterol is also 
associated with impaired surfactant activity in ALI/ARDS [28], this study also 
aims to address if addition of Mini-B is sufficient to counter the negative effects of 
elevated amounts of cholesterol.  
  In addition to investigating the surface tension lowering ability of these 
model LS mixtures, we report on the changes in the compressibility modulus of 
the lipid films, and correlate these changes with changes in the lipid domain 
morphology and line tension. Domain morphology has an impact on the 
viscoelasticity and the compressibility of a monolayer [29], which in turn controls 
spreading, and the ability of these different monomolecular films to undergo 
reversible collapse. Reversible collapse is an important feature of LS, believed to 
be essential for efficient incorporation of material during the breathing cycle, by 
forming “surface-associated reservoirs” [30] at ultra-low surface tension. Further, 
some of us have also previously shown that SP-B causes an increase in the line 
tension of a clinical lung surfactant, an important biophysical property of 
phospholipid films at the air-water interface, which can control the overall energy 
of the lipid films [29]. By correlating high-resolution atomic force microscopy 
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(AFM) images to calculations of line tension changes in different binary lipid 
films, we have also recently shown that a change in line energy can be directly 
related to the tendency of a molecule to act as a line active species [31]. Further, 
previous research by McConnell and co-workers has established the line tension 
lowering ability of cholesterol [32]. However, quantitative information on how 
Mini-B and cholesterol alter the domain morphology and therefore the line 
tension between lipid domains is currently not available.  Therefore, by applying 
our recently developed theory relating domain size distributions to changes in the 
excess free energy between lipid domain boundaries (line tension between 
domains), we also report on the line tension of lipid films due to Mini-B 
cholesterol interactions. 
 At this point I would like to mention that part of this study had been 
communicated earlier through the Master’s thesis. However, this chapter consists 
of some additional findings that help in providing a better picture to understand 
the biophysical properties of the system under consideration.  
  
2.2. MATERIAL AND METHODS 
2.2.1 Material: The lipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) and 
cholesterol were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) in 
powder form for cholesterol and at final concentrations of either 25 mg/ml or 5 
mg/ml in organic mixtures of chloroform for the others. The synthetic protein Mini-
B a mimic of the native surfactant protein SPB [26, 33] was supplied by 
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Biopolymer Core Facility, LA BioMed at Harbor UCLA Medical Center, Torrance, 
California. Organic solvents, acetone, isopropanol and chloroform, were 
purchased from Thermo Fisher Scientific Inc. (Pittsburgh, PA). The fluorescent 
dye,1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine, Triethylammonium 
Salt (TXR-DHPE), was obtained from Life Technologies (Invitrogen, Grand 
Island, NY) in dried form. The lipids were stored at -20 oC to prevent any 
evaporation of the organic mixture. Water, which served as a sub-phase as well 
as cleaning agent, was purified (resistivity of 18.2 MΩ cm) using Direct-Q 3 UV 
System purchased from EMD Millipore (Billerica, MA).    
4.2.2. Methods:  
2.2.2.1. Sample Preparation: Organic solutions of DPPC:POPG in high 
performance liquid chromatography (HPLC) grade chloroform were prepared in 
the ratio of 7:3 by weight as DPPC is the primary composition of LS. 1wt.% dye 
was used for imaging purposes. Mini-B stock solutions were prepared in a 3:1 
mixture of chloroform and methanol before being added to organic LS mixture.  
Multiple compositions of Mini-B (1, 2.5, 5 wt. %) and Cholesterol (1, 2.5, 4, 5 wt. 
%, which corresponds to 2, 5, 7, 9 mol %) were used along with DPPC:POPG 
(7:3 molar ratio).  
 
2.2.2.2. Surface Pressure vs. Mean Molecular Area Isotherm: Surface 
pressure vs. area isotherms were obtained using a Langmuir trough (Biolin 
Scientific Inc.), with a area of 166 cm2 and minimum area of 46 cm2. It uses a 
moveable ribbon that serves as barrier to control the available area per molecule, 
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which thus mimics the compression and expansion process in the alveoli. 
Samples were added drop wise with a Hamilton glass syringe on an aqueous 
sub-phase and 20 minutes were given each time before running the experiment 
to allow the chloroform to evaporate. For isotherm experiments a compression 
rate of 125 cm2/ min was chosen. Surface pressure was measured using 
Wilhelmy plate balance (filter paper). All experiments were repeated at least 
three times, to ensure reproducibility. All three sets of isotherms were found to 
overlap.  
2.2.2.3. Fluorescence Imaging: A Nikon Eclipse fluorescence microscope was 
used to visualize the lipid domain formation on the air-water interface. For 
imaging purposes a slower, quasi-static, rate of 7 cm2/ min was selected. The 
images, at intervals of 1 to 5 mN/m (in the two-phase coexistence region), were 
captured using CCD camera (Andor LUCA). 5 frames were used for each image 
sequence and the representative images are presented in this report. Images 
were analyzed for calculations with ImageJ (NIH) software. Two neighboring 
images were analyzed for each image sequence for better statistical quality. This 
typically meant that at least 270 domains were analyzed to obtain the domain 
size distribution for each lipid composition. Furthermore, the circularity of the 
domains can also be measured using ImageJ. All final histograms and line 





2.3. THEORETICAL ANALYSIS  
2.3.1. Compressibility modulus: The compressibility modulus or modulus of 
elasticity b,  of the film  is often used to describe the properties of the monolayer 
film. It is defined as the ability of a film to store mechanical energy as stress 




















     
  …1 
The inverse of b yields the isothermal compressibility k of the film. Since b and k 
are 2nd order derivatives of the surface free energy, G, ( ( )TAG ∂∂−= /σ ), 
discontinuities in these values confirm the presence of phase transitions. 
Experimentally, the phase transitions are represented as a blunt dip in the b-A 
profile rather than a sharp discontinuity.  
The compressibility modulus is calculated from the raw isotherm data by 
calculating the slope m of the isotherm (P-A) at each point using the formula 































     
    …2 
The derivatives can give rise to high-frequency, low-amplitude noise arising from 
fluctuations in the surface pressure reading as a result of discretization, which 
can be safely removed by a Fourier smoothing filter. The derivative and the 
Fourier smoothing filter are tools that are available as in-built functions through 
Origin 8.62, the graphing software used here for the isotherm data analysis.  
	 44	
 2.3.2. Condensed Area Fraction: The condensed area fraction of domains 
provides us with an estimate of the fraction of the monolayer that forms ordered 
domain structures at a given surface pressure. Mathematically, the percentage 






2.3.3. Determining line tension from domain size distribution:  
The line tension (λ) between lipid domains depends on the difference in the 
height of the lipid chain,  between the molecules in the liquid condensed (lo) and 
liquid expanded (ld) regions, and the interfacial tension of the hydrocarbon-air 
interface (γ) [i.e., λ = (lo-ld)γ]. On the other hand, the average dipole density 
(Δm2), which in turn is related to the electrostatic energy of the domains, 
depends on the packing density and composition of the lipid domains. The shape 
of the condensed domains in a monolayer is thus a function of the energy 
associated with the line tension and electrostatic repulsion. A method to 
simultaneously calculate the line tension and the dipole density moment from the 
distribution of circular phospholipid domains has been shown previously [29]. 
Using this method, we have shown that the line tension, λ can be related to the 




X 100 % 
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radius (i.e., ratio of mole fraction of molecules in N to the number of domains, N, 
given by XN/N) by the following equation:  
 
   
…4 
 
          
…5 
                    
The domain distribution, which is obtained experimentally, is then fitted with 
equation (4). Here we use CM, Δm2Ro/ 4εεokT, and Ro as the three fitting 
parameters. Equation 5 is next used to determine the line tension. 
2.4. RESULTS 
2.4.1. Isotherms: Figure 1 presents the quasi-static surface pressure vs. mean 
molecular area isotherms of the different samples examined. Fig 1A shows how 
the isotherm of a mixture of DPPC:POPG was modified by varying the 
concentration of Mini-B. The solid line represents the control curve for 
DPPC:POPG.  At higher mean molecular areas, the monolayer is in the gas 
phase and therefore at 0 surface tension. However, the surface pressure 
increases with decrease in the mean molecular area, until finally the monolayer 
reached collapse pressures (~ 72 mN/m). With the addition of 1% Mini B to the 




Fig 1: Surface pressure vs. mean molecular area isotherms for different lung 
surfactant mixtures. (A) DPPC:POPG (7:3) with 1% and 5% Mini-B. (B) DPPC:POPG 
with 1% and 5% cholesterol. (C) DPPC:POPG with 1% Mini-B and varying concentration 
of cholesterol (D) DPPC:POPG with 5% Mini-B and different weightage of cholesterol. 






However, when 5 % Mini B was added to DPPC:POPG, given by the dotted line, 
the isotherm moved to higher values of surface pressure at any given mean 
molecular area. Fig 1B represents the effect of varying amounts of cholesterol on 
the isotherm of DPPC:POPG, while Fig 1C is a plot of DPPC:POPG mixed with 
1% Mini-B and varying composition of cholesterol. The isotherm for Mini-B 1% 
and Cholesterol 1%, given by the dashed curve, shows that the isotherm was 
pushed to higher values of surface pressure for the same mean molecular area. 
Increasing the concentration of cholesterol to 5 % caused the surface pressure 
vs. area curve (dotted lines) to fall back close to the control. Fig 1D represents 
the effect of 5% Mini-B with varying amounts of cholesterol on DPPC:POPG. The 
isotherms moved further to lower mean molecular areas indicating the need for 












Fig 2: Compressibility Modulus for different lung surfactant mixtures. (A) 
DPPC:POPG (7:3) with 1% and 5% Mini-B. (B) DPPC:POPG with 1% and 5% 
cholesterol. (C) DPPC:POPG with fixed Mini-B percentage (1%) and varying weightage 
of cholesterol (D) DPPC:POPG with 5% Mini-B and different amounts of cholesterol. 






2.4.2. Compressibility Modulus: Fig 2 presents the compressibility modulus as 
a function of mean molecular area of the samples tested. The data was 
processed using an FFT filter over 5 points, except near the collapse. Fig 2A 
shows the compressibility modulus for varying composition of Mini-B with 
DPPC:POPG. In case of the control DPPC:POPG sample, the compressibility 
modulus increased gradually till it reached around 31 mN/m after which there 
was a slight dip in the curve. The peak value of compressibility modulus before 
monolayer collapse was found to be 109 mN/m. In case of DPPC:POPG 
monolayers containing 1% Mini-B, presented as dashed lines, there was almost 
no change in the compressibility modulus till 32 mN/m. In place of the dip in the 
curve beyond this value, like that of the control, there was a plateau until 46 Å2/ 
molecule. The peak compressibility modulus was found to be around 98 mN/m. 
With 5% Mini-B, the peak compressibility modulus was measured to be 112 
mN/m at 26 Å2/ molecule. Fig 2B shows the effect of different concentration of 
cholesterol on the compressibility modulus of DPPC:POPG. In case of 1% 
cholesterol the peak compressibility modulus was found to be 97 mN/m and at a 
higher value of mean molecular area than that of the control DPPC:POPG film. 
DPPC:POPG films containing 5 % cholesterol showed a gradual rise in the 
compressibility without a dip. The maximum compressibility dropped to 91 mN/m 
and also shifted to even higher mean molecular areas (29 Å2/ molecule). Fig 2C 
gives the compressibility modulus for systems containing both Mini-B and 
cholesterol. With Mini-B 1% and cholesterol 1% (dashed curve), there was an 
increase in the compressibility of the mixture. We noted the highest 
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compressibility in this case, (137 mN/m) at a mean molecular area of 27 Å2/ 
molecule. For 1% Mini-B and 5 % cholesterol (dotted line), the curve increased 
gradually to a value of 92 mN/m at 27 Å2/ molecule. Fig 2D represents the 
compressibility modulus of DPPC:POPG along with 5% Mini-B and varying 
concentration of cholesterol. In case of 5% Mini-B and 5% cholesterol, the peak 
was as low as 50 mN/m at 27 Å2/ molecule, indicating a substantial change in the 
mechanical property due to Mini-B cholesterol interactions.  
2.4.3. Fluorescence Images: To have a detailed understanding of the changes 
in the domain morphology in the monolayer, we used fluorescence microscopy 
imaging to monitor changes in lipid domains during the compression cycle. We 
present here images at surface pressures 20 mN/m. At 20 mN/m, the monolayer 
shows coexistence between two phases, namely the bright Liquid Expanded (LE) 
and the dark Liquid Condensed (LC) phases.  
Fig 3A shows the images for DPPC:POPG (7:3) at surface pressures 
20mN/m. In case of the control, the monolayer is well packed agreeing with that 
found in literature [34]. The domains were more or less circular in shape at lower 
surface pressure. Fig 3B shows the images for DPPC:POPG (7:3) with 1% 
cholesterol added to the system. Here we observed a drastic change in the 
domains. In place of the circular condensed regions of DPPC:POPG, we found 
protruding curls along the boundaries of the domains. The effect became more 
pronounced with the rise in the surface pressure. Fig 3C shows the effect of 5% 
cholesterol, where the domain morphology had transitioned from circles to thin, 



















Fig 3: Fluorescence images of DPPC:POPG (7:3) along with varying 
concentrations of Mini-B and cholesterol. Images A, B, C, D, E, F, G, H and I were 
taken at 20 mN/m, which corresponds to the two-phase coexistence region. The first row 
represents samples without Mini-B, the next row represents samples with 1% Mini-B in 
them, and the last row contains sample with 5% Mini-B. Concentration of cholesterol 
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A noticeable decrease in dark condensed domains was recorded, that we 
quantified in Fig 5. Fig 3D shows that adding 1% Mini-B to DPPC:POPG shows a 
slight decrease in the packing density of the dark domains, which increases with 
increasing protein concentration, as seen in Fig 3G after addition of 5% Mini-B. 
Fig 3E shows the monolayer consisting of both 1% Mini-B and 1% cholesterol, 
where an interesting new morphology of crescent shaped domains were 
observed. With 1% Mini-B and 5% cholesterol (Fig 3F) the domains were 
completely transformed without getting packed at all. Fig 3H shows the effect of 
1% cholesterol along with 5% Mini-B. There were no appreciable changes in the 
shape of the domains when compared to DPPC:POPG film containing Mini-B 
only, showing that the higher concentration of Mini-B dominated over the lower 
percentage of cholesterol. Finally, at 5% Mini-B with the same concentration of 
cholesterol added to DPPC:POPG (Fig 3I), the domains were smaller, but still 
circular in shape. 
2.4.4. Ability to retain material during multiple compression-expansion 
cycles: When the monolayer is compressed to the limit of its stability, it 
transitions from its 2-dimensional existence to a 3-dimensional one. This 
phenomenon has been termed “monolayer collapse” and has been studied 
extensively by biophysicists due to its relevance to more efficient breathing [35, 
36]. The mechanism of collapse can either be reversible or irreversible in nature. 
Reversible collapse typically suggests formation of surface associated reservoirs, 
that enable quick and efficient re-adsorption of material during multiple 
compression-expansion cycles, and is believed to be desirable for efficient LS 
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mixtures.  The fluorescence-intense “streaks” seen in the images (Fig 4A-E, 
indicated by arrows), which are found perpendicular to the direction of 
compression, are the reversibly collapsed regions, commonly known as “folds” or 
“collapse cracks” [36]. Here, the monolayer folds into multi-layers and upon 
expansion, the folded component respreads. Formation of giant folds, which 
extends a few microns laterally, indicates lower loss of material to the sub-phase.  
Monolayers lacking such folds, collapses irreversibly and solubilization is the 
likely mechanism when fluidizing agents, such as cholesterol, is present in the 
monolayer. Irreversible collapse due to solubilization of material is characterized 
by formation of vesicles, which are visible as bright specks in the images. It has 
been reported earlier that DPPC:POPG (7:3) on its own produces thin folds after 
collapse [37] and Fig 4A shows similar results. Fig 4B and 4C reveals that Mini-B 
helped DPPC:POPG to form fluorescence-intense giant folds suggesting 
reversible collapse. These features are very similar to that reported for KL4 [37].  
With the addition of 1% cholesterol to 1% Mini-B (Fig4D) or 5% Mini-B (Fig 4E), 
the monolayer collapsed reversibly.  However, 5% cholesterol along with 5% 
Mini-B showed irreversible collapse (Fig 4F). In order to further prove that the 
formation of these features correspond to better incorporation of material during 
multiple compression cycles, we also present the surface pressure vs. area 
isotherms for multiple cycles. In order to represent material loss, we also plot the 
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Fig 4: Fluorescence images of DPPC:POPG and a combination of Mini-B and 
cholesterol, revealing collapse at higher surface pressures (A-F). Arrows indicate 
“collapse crack”. (A'-F') Isotherms with multiple compression cycles for the same 
samples (A'-F'). (A"- F") Mean and standard deviation of the area within the curve for 
each cycle for the same samples. Scale bar represents 10 µms. The area under the 
curve is given as *10-4 mN-m.  (Figs A-F has been taken from the Master’s thesis) 
 
An increase in the area of the isotherm suggests more material at the surface, 
while a significant drop in the area within the curve suggests loss of material from 
the surface. Fig 4A’ shows multiple compression-expansion cycles for 
DPPC:POPG while 4A" shows the corresponding area of the curve for the 1st 
and 3rd cycle. With multiple compressions, the isotherm shifted to lower fractional 
trough area. However, in case of 1% and 5% Mini-B, this loss appeared to be 
reduced (Fig 4B', B" and Fig 4C', C"). Higher concentration of Mini-B (5%) along 
with small concentration of cholesterol (1%) showed the least loss in material 
(Fig 4E', E").  
         Furthermore, One-way-ANOVA revealed a significant difference (α=0.05) in 
the area of the 1st cycle between the different samples (F6,14= 9.036, p= 
3.72*10^-4, R2= 79.48%) as well as the area of the third cycle between the 
different samples (F6,14 = 15.22045, p = 2.062* 10^-5, R2= 86.71% ).  
2.4.5. Percentage Condensed Region: Fig 5 shows the percentage of the 
monolayer that was condensed due to the addition of cholesterol and Mini-B 
to DPPC:POPG films. Surface pressures 15, 20, 25 and 30 mN/m were 
chosen for this analysis, since at higher surface pressures analysis of individual 
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domains was no longer possible, and the entire field of view appeared dark. Fig 
5A shows the effect of Mini-B on DPPC:POPG. The condensed domain 
increased from 50% to about 55% with rise in surface pressure in case of the 
model system. However, with the addition of Mini-B, at initial surface pressures 
there was a reduction in the condensed domains. The effect was more 
pronounced when higher percentage of Mini-B was added to the model mixture. 
Fig 5B shows how cholesterol alters the formation of condensed domains in the 
model mixture. Even in this case, there is a decrease in the area of condensed 
domains with the addition of cholesterol. The next two figures reveal how Mini-B 
and cholesterol both act together in altering the area of the dark domains. Fig 5C 
contains the data for 1% Mini B and varying concentrations of cholesterol. Here, 
with 1% of both put together, there was a steady increase in the domain area at 
25 and 30 mN/m suggesting better domain packing. However, 1% Mini-B and 5% 
cholesterol showed a reduction in the area of the condensed domains. Fig 5D 
shows the effect of varying amount of cholesterol on 5% Mini-B. In this case, 5% 
Mini-B was able to maintain the percent of condensed domains to almost that of 





Fig 5: Percentage condensed domains for varying mixtures of DPPC:POPG (7:3). 
Percentage condensed domains due to addition of (A) different weights of Mini-B on 
DPPC:POPG (B) cholesterol (C) 1% Mini-B with different concentrations of cholesterol 






However, in the presence of higher cholesterol content, the area reduced 
drastically. This showed the dominance of higher concentration of cholesterol 
even with equal amount of Mini-B. The error in measurement was particularly 
high for the mixture with 1% Mini-B and 5% cholesterol mainly because of the 
difficulty in determining the condensed area owing to the small size of the 
domains, which made the analysis difficult. The error for the remaining mixtures 
was less than 10% of the total condensed area.  
2.4.6. Line Tension: 
The theoretical calculations relating line tension to domain size distribution, is 
only feasible for lipid domains that are circular in shape. Therefore, we were 
limited to calculating and presenting the line tension of the domains for the 
control, lipid mixture with both 1% and 5% Mini-B and the mixtures that had 5% 
Mini-B and varying concentration of cholesterol. Surface pressure 20 mN/m was 
selected for the ease of analysis. The line tension of DPPC:POPG (Fig 6A) was 
around 2.4 x 10-2 pN. With the addition of 1% Mini-B, line tension increased to 
about 5 x 10-2 pN. Line tension in case of 5% Mini-B was slightly higher than that 
of 1%. When 1% , 2.5% and 4% cholesterol was added to 5% Mini-B (Fig 6B), no 
significant change in line tension was noted, even though cholesterol has been 
shown to reduce line tension [20]. However, increasing concentration of 





















Fig 6: Changes in line tension for different mixtures. Line tension between the 
domains in DPPC:POPG lipid films containing (A) different weights of Mini-B and SP-B, 










This work is motivated by the desire to understand the biophysical interactions 
between cholesterol and synthetic surfactant protein Mini-B in a synthetic LS 
mixture.  Kim et al. have shown that even 1 wt. % cholesterol is capable of 
reducing the surface viscosity of DPPC monolayer by an order of magnitude 
whereas 2 wt. % is capable of reducing the viscosity by two orders of magnitude 
[20]. This characteristic feature is valuable and is therefore a desirable property 
in synthetic surfactant because lowering of the surface viscosity can help in 
uniformly distributing the LS mixture throughout the lungs, as well as re-
spreading of the surfactant with the expansion of lungs. However, as noted in the 
introduction, cholesterol is a highly debated component of LS and most of the 
commercial drugs used in SRT avoid cholesterol. Our own results confirm that 
not surprisingly, in the absence of protein Mini-B, even physiological amounts of 
cholesterol cannot maintain the desirable high surface pressures necessary 
during exhalation in case of a synthetic binary LS mixture. Similarly, even 1% 
cholesterol prevent DPPC:POPG films from collapsing by forming surface 
associated reservoirs (reversible collapse), possibly by lowering the 
compressibility modulus of the film. On the other hand, 1wt. % Mini-B alone is 
enough to significantly improve the ability of DPPC:POPG to undergo reversible 
collapse. Thus Mini-B and cholesterol demonstrate seemingly opposing 
biophysical characteristics, which when optimized, is expected to provide 
synthetic surfactant mixtures with enhanced therapeutic potential. Our results 
show that small quantities of cholesterol and Mini-B can together enhance the 
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properties of LS. We discuss these results in further details in the following sub-
sections. 
 
2.5.1. Effect on Mechanical Properties: 
The surfactant mixture DPPC:POPG is efficient in lowering surface tension to 
near zero values owing to the presence of the disaturated phospholipid which 
has been reported previously [38]. Pressure vs. area isotherms suggests that 
higher amounts of Mini-B can cause early condensation of lipid domains, leading 
to higher surface pressures at the same area per molecule. On the other hand, 
cholesterol has a negative impact on the performance of DPPC:POPG films at 
higher surface pressures. Here, more area compression is needed to achieve the 
desired high surface pressure values. However, monolayers containing 1% of 
both the components, Mini-B and cholesterol together, are capable of enhancing 
the surface activity. Moreover, compressibility modulus of the system, which can 
be derived directly from the pressure vs. area isotherm [39], was found to be the 
highest for the above mixture. A highly compressible mixture can form well-
packed structure, which again is supported by the fluorescence images. The 
compressibility modulus is much lower in case of mixtures containing higher 
percentage of the two additives. Further, the isotherms for multiple cycles also 
show that these components together can improve the incorporation of material 




2.5.2. Effect on Line Tension and Collapse: 
Cholesterol and Mini-B alone have contrasting effects on the line tension of the 
LS films, as well as its ability to undergo reversible collapse. It is well known that 
cholesterol can lower the line tension between lipid domains to near zero values, 
as evidenced by the formation of spiral structures in the presence of cholesterol 
only [20]. On the other hand, our analysis of the domain size distribution shows 
that Mini-B increased the line tension between lipid domains. This finding is not 
surprising. Native SP-B was also found to increase the line tension between 
domains in a clinically relevant surfactant mixture [29]. We have previously 
attributed this increase in the line tension to the tendency of the positively 
charged protein to associate with the negatively charged POPG lipids that are in 
the fluid regions of the lipid membrane.  It was interesting to note that in the 
presence of 5 wt. % Mini-B, 1-4 wt. % cholesterol did not lower the line tension 
between lipid domains, suggesting that interactions of the Mini-B with the 
negatively charged POPG lipid dominates over the protein cholesterol 
interactions, or cholesterol’s tendency to associate with domain grain boundaries.   
Finally, the packing density between lipid domains was also high when both 1% 
Mini-B and 1% cholesterol were present. Further, this mixture was capable of 
collapsing reversibly, unlike the films containing cholesterol alone that were 





2.6. CONCLUSION  
Based on our experimental observations, we conclude that any potential negative 
effects of low concentrations of cholesterol on the line tension, reversible 
collapse, and compressibility of synthetic LS mixtures, can be countered with 
synthetic protein Mini-B. However, higher concentration of cholesterol cannot be 
used as it has a greater negative impact on the model surfactant mixtures used 
in this study. For further exploration, smaller concentration of cholesterol along 
with 1% to 5% Mini-B can be tested in case of SRT to allow the surfactant to be 
fluid enough to effectively cover the interface at inhalation, while resisting 
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Chapter 3: Impact of ECN on the Collapse Mechanism of Lung Surfactant 














Langmuir monolayers of amphiphilic molecules at air-water interface go 
through 2D phase transitions when compressed [1]. This transition of the 
monolayer from the air-water interface to the aqueous sub-phase is defined as 
monolayer collapse. A detailed review of the different mechanisms of the 
monolayer collapse has been presented by Lee et al. [2]. The squeeze out 
hypothesis is one key mechanism. In this case, complex amphiphilic mixtures are 
prone to a rejection of molecules from the surface before reaching the limiting 
area of compression. Collapse following this path is deemed irreversible. In this 
case, a loss in the material at the interface is inevitable. However, in the case of 
naturally occurring lung surfactants (LSs), the molecules remain closely 
associated with the surface. Studies have shown that LS proteins or their 
synthetic analogs are capable of eliminating the squeeze out [3-5]. Thus, the 
collapse following this pathway is reversible, and the material is reincorporated in 
such monolayers upon expansion. In this report, we are concerned with the 
impact on the reversibility of phospholipid monolayers in the presence of 
Engineered Carbon Nanodiamonds [ECN]. The phenomenon of collapse and 
material loss is particularly interesting in the world of LSs as these monolayers 
undergo multiple compression/expansion cycles.  
LSs are a class of amphiphilic mixtures that are present in the alveolar 
lining of the lungs [6, 7]. Native surfactants are made up of 90% by weight lipids 
and 10% by weight proteins. Because of the complexity of the native material, 
simple model mixtures are often used to mimic the interfacial properties of the 
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surfactants. The most prevalent amongst the lipids are the zwitterionic, 
disaturated dipalmitoylphosphatidylcholine (DPPC), and therefore DPPC is 
selected as the primary component of the representative LS mixtures. The other 
phospholipids that are usually selected are the unsaturated phosphatidylcholine 
as well as the negatively charged, unsaturated phosphatidylglycerol. The primary 
function of the LSs is to lower the surface tension of water with exhalation [8, 9]. 
This	 reduction in surface pressure, in turn, decreases the energy required for 
breathing, improving lung compliance. Additionally, the monolayer of LSs forms a 
barrier for foreign particles that are capable of reaching the alveoli [10]. 
Therefore, any foreign object capable of interfering with the regular functioning of 
LSs must be carefully examined, and this forms the primary motivation for our 
work.  
With the advancement in nanotechnology, engineered nanoparticles have 
been gaining significant grounds in different areas including biomedicine [11-14]. 
The small size of the particles as well as relative ease in surface-tunability, these 
nanoparticles are suitable vehicles for targeted drug delivery amongst other 
biomedical applications [15, 16]. Therefore, it is highly likely for nanoparticles to 
either intentionally or unintentionally enter human bodies, and it is necessary to 
evaluate the compatibility and the toxicity of the nanoparticles when interacting 
with various physiological components. In this regard, the respiratory tract is one 
common route for the entry of the nanoparticles. The small size allows the 
particles to reach the depths of the alveoli [17]. Upon entering the alveoli, 
nanoparticles then interact with LS monolayer. Research has shown the impact 
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of size, hydrophobicity, and concentration of different nanoparticles on the 
functioning of surfactants [18-21]. In the past, we have demonstrated the effect of 
phospholipid headgroup charge and tail saturation on the packing and domain 
formation, especially in the Liquid Expanded [LE]-Condensed [C] coexistence 
region of the monolayer when interacting with the increasingly popular ECNs 
[22]. We observed that at lower surface pressures, the anionic ECNs behave as 
line active species when interacting with zwitterionic phospholipids. But, in the 
presence of anionic phospholipids, electrostatic repulsion plays a greater role. 
Thus, at low compressions, the composition of the phospholipids also contributes 
to the behavior of the nanoparticles. However, in the current report, we focus on 
the impact of ECNs on the collapse mechanism of LS monolayers. Reversible 
collapse accompanied by material preservation is ideal for LS mixtures. For our 
work, we selected four phospholipid mixtures that represent the two mechanisms 
of collapse. ECN was selected because of the growing interest in these particles 
for both diagnostic and therapeutic applications [23].  
 
3.2. MATERIAL AND METHODS 
3.2.1. Material. The phospholipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
[DPPC], 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 
[POPG], 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine [POPC], 1,2-dipalmitoyl-
sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) [DPPG], and  1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine [DPPE] were obtained from 
Avanti Polar Lipids (Alabaster, AL). The phospholipid mixtures were purchased in 
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chloroform mixtures at concentrations of 5 or 25 mg/ml. The phospholipid dye 
that was used in our study, Texas red 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt [TXR-DHPE], was obtained from 
Life Technologies (Invitrogen, Grand island, NY). The engineered carbon 
nanodiamonds were procured from Microdiamant, Lengwil, Switzerland. The 
phospholipids as well as the dye were diluted to 1 mg/ml in high-performance 
liquid chromatography (HPLC)-grade chloroform before using them in our 
studies. ECN suspensions were also prepared in the chloroform:methanol 
solutions. Chloroform, methanol, acetone, and isopropanol used in this study for 
preparing samples and cleaning equipment, were purchased from Thermo Fisher 
Scientific Inc. (Pittsburgh, PA). The water, used as the cleaning agent and sub-
phase, had a resistivity of 18.2 MΩ/cm), which was prepared in a Millipore 
gradient system (Billerica, MA). 
3.2.2. Methods. Sample Preparation: Table 1 shows the phospholipid-ECN 
solutions used in our study. Solutions of DPPC:POPG, DPPC:POPC, 
DPPC:DPPG, and DPPC:DPPE mixtures (7:3 by weight) were prepared in 
chloroform. 1 weight % TXR-DHPE dye (dissolved in 4:1 chloroform:methanol 
mixture) was added to the lipid samples. Carbon nanodiamonds suspensions 
were sonicated for 2 hours, and immediately afterward, stoichiometric volumes 




Table 1: The table lists the samples that have been used in the study. The phospholipid 
mixtures were taken in the ratio of 7:3 by weight, keeping the percentage of DPPC 
maximum. The samples with 1 weight % ECN were compared with their counterpart, 
control that had no ECN in the mixture. 
 
3.2.2.1. Langmuir Studies: Nanodiamonds were mixed with the lipid samples, 
sonicated for 2 hours and added dropwise on the surface of ultrapure water 
contained in a Langmuir Ribbon Trough, which was purchased from Biolin 
Scientific Inc. (Phoenix, AZ). The trough consists of movable ribbon that can 
compress/expand such that the molecules on the surface can go through 
different phases. The multiple compression and expansion cycles serve as a 
model that mimics the decrease and increase in the alveolar area with 
exhalation/inhalation. The maximum area of the trough is 166 cm2, and the 
minimum area is 46 cm2, which provided the samples with enough area to reach 
high surface pressure values upon compression. Furthermore, the ribbon is 
computer controlled to move at a uniform rate with the help of the software 
supplied by Biolin Scientific Inc. After spreading the sample solution on the water 
surface and before starting the compression/expansion cycles, the chloroform 
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was allowed to evaporate for 20 minutes. This waiting period also provides 
sufficient time for the monolayer to spread uniformly on the surface. After the 20-
minute period, the ribbon was moved at the rate of 125 cm2/min for the 
compression/expansion isotherms. However, in the case of fluorescence 
imaging, a slower rate of 7.0 cm2/min was used for clarity.  
3.2.2.2. Fluorescence imaging: The trough is also coupled with a Nikon Eclipse 
fluorescence microscope for visualizing the surface morphology of the 
monolayer. The microscope is equipped with a 40X- long working distance 
objective lens along with motorized-focusing capabilities that allow us to monitor 
the surface of the monolayer continuously. A dichroic mirror/ barrier filter 
assembly is used in this setup to direct the excitation light perpendicular to the 
monolayer, whereupon, the emitted light is filtered and captured by the 
microscope coupled with a fast CCD camera (Andor Luca). For our purposes, we 
recorded images in sequences of five to observe the morphology.  
 
3.3. THEORETICAL ANALYSIS 
3.3.1. Analysis of Material Loss. Area under the curve and percentage 
recovery: Surface pressure versus area isotherms provides evidence of 
interaction between molecules at the interface.  Upon compression, the 
monolayer transitions from one phase to the next because of an increase in the 
surface pressure. At high surface pressures, the monolayer no longer remains as 
a 2-dimensional film on the surface of the water. Instead, it becomes too unstable 
and excludes material to the bulk solution (ultrapure water in our case). As a 
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result there is a loss of material from the surface. Furthermore, with the 
progression of compression/expansion cycles, the isotherm shifts to lower areas, 
which is indicative of the aforementioned loss in material. Therefore, we focused 
on analyzing the area under the curve (hysteresis) of the samples tested. A 
lowering of such area shows the extent of material loss, which is one of the 
primary focuses of our study.  
3.3.2. Model based on Volmer’s Equation of state for the prediction of the 
Π-A isotherm at the region of 2-Dimensional coexistence phase: Equations 
of state [EOS] at the air-water interface can be used to predict the two-
dimensional phase coexistence region of the Π-A isotherms of amphiphilic 
monolayers. Fainerman and Volhardt have described such EOS for insoluble 
Langmuir monolayers, which is capable of predicting the Π-A isotherms at the 
gaseous region as well as the 2D phase transition for single amphiphile [24]. 
Another theoretical model published by the same group describes the liquid 
expanded region of the Π-A isotherms of different amphiphilic molecules [25]. 
Recently, Ghazvini et al.  used the theoretical model proposed by Feinerman and 
Volhardt to understand the impact of pH on the packing of phospholipid 
membranes [26]. Furthermore, these equations are also capable of predicting the 
material loss. Here, we represent the key equations that have been used in the 
present work to quantify the material loss at the interface.  





               …2 
Here, π represents surface pressure of the monolayer, k is the Boltzmann 
constant, T is the temperature, ω is the average effective molecular area of the 
insoluble species, ωo is the molecular area per water molecule, A is the available 
surface area per insoluble molecule, and πcoh is the cohesion pressure. However, 
the available surface area, A, requires the knowledge of the number of 
molecules, n, at the surface. Mathematically, A can be related to the trough area, 
AT, as follows: 
A = AT/n 
               …3 
Therefore, we used a modified Volmer’s equation, derived by Kuo et. al. [27], 
represented in equation 4, to characterize material loss from the surface.  
 
                              …4 
Here, ωeff is an effective total molecular area, and is given by,  
ωeff = n ω 
               …5 
Equation 4 can be directly fitted to the π-A isotherms. Additionally, ωeff helps us 








Fig 1. (A) Surface Pressure versus area of the trough isotherms for DPPC:POPG (7:3) 
without (control, red solid line) and with 1 wt. % ECN (black solid line). All samples were 
compressed and expanded five times. The solid arrows point to the direction of 
compression curve and the expansion curve on the isotherms. The dashed arrow on the 
other hand shows the direction of advancement of the compression/expansion cycles. 
All data has been represented as the mean of 3 samples. (B) Area under the curve as a 
function of compression/expansion cycle for DPPC:POPG (7:3) without (control, red 
square) and with 1 wt. %  ECN (black square). A sample size of three was used for 




3.4.1. Isotherms and area under the curve of DPPC:POPG. Figure 1A shows 
the quasi-static surface pressure versus mean molecular area isotherm of 
DPPC:POPG monolayer without (red solid line) and with (black solid line) 1 wt% 
ECN. Mathematically, surface pressure can be written as,  
Π = γo - γ 
     …6 
Where, γo is the surface tension of water and γ is the surface tension of 
monolayer. Initially, at higher area of exposure, the molecules are spread far 
apart. As the film is laterally compressed, the molecules come closer together 
and there is an increase in the surface pressure. This leads the monolayer to 
transition from the gaseous phase to the LE phase. In the case of DPPC:POPG 
isotherms, we observe that the monolayer is in the LE phase around 10 mN/ m of 
surface pressure. Beyond this Π, the phase coexistence region appears, where 
the monolayer consists of both LE and C phase. As the surface area is further 
reduced, Π increases sharply until 65 mN/m. After this pressure point, the 
monolayer undergoes a final collapse, encountering a decreasing slope in the 
isotherm, and reaching pressures of around 72 mN/m eventually. Once the 
monolayer is fully compressed, the expansion phase begins, and the surface 
pressure drops rapidly without any notable change in the surface area. The drop 
continues around 15 mN/m after which the decrease in slope becomes gradual. 
Here, the expansion curve follows a different path from the compression curve, 
and therefore, the isotherm displays hysteresis. Multiple reasons have been 
considered to explain this hysteresis in the Π–A isotherm of lung surfactant 
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monolayers [28]. Alteration in the compositional ratio after expansion may lead to 
hysteresis. Also, ejection of material from the surface that fails to/ slowly 
reincorporates with expansion may also contribute towards hysteresis. Further 
compression/expansion cycles shifts the isotherms towards lower areas of the 
trough. This shift in the Π–A isotherm is because of a loss in material from the 
surface. The DPPC/POPG isotherms exposed to 1 wt% ECN shifts negligibly to 
higher molecular areas initially. Furthermore, the slope of the curve remains 
identical to that of the control. However, larger hysteresis is seen in this case. 
Additionally, with repeated compression/expansion cycles, the isotherm shifts to 
lower areas of the trough.  
To quantify the material loss, we calculated the integral area under the 
curve for each compression/expansion cycle. The log-transformed area under 
the curve for DPPC:POPG has been shown in Figure 1B. In the case of the first 
cycle for control, the area under the curve is around 3.45 in the logarithmic scale. 
After the first isotherm, there is a notable drop in the area under the curve. This 
drop in the value indicates loss in material from the interface. For the second 
isotherm, the value is about 3.18, and the area keeps dropping till the fifth 
isotherm, where the value is as low as 2.8. With the addition of the 
nanodiamonds, we see an increase in the area to about 3.5 for the first isotherm. 
This suggests the incorporation of the nanoparticles at the interface. The 
subsequent cycles show decrease in the area with the fifth cycle reaching about 





Fig 2. (A) Surface Pressure versus area isotherms for DPPC:POPC (7:3) without 
(control, red solid line) and with 1 wt % ECN (black solid line). Similar to the 
DPPC:POPG, DPPC:POPC samples were compressed and expanded five times. The 
data has been represented as the mean of 3 samples. (B) Area under the curve as a 
function of compression/expansion cycle for DPPC:POPC (7:3) without (control, red 
square) and with 1 wt. %  ECN (black square). Three samples were taken to obtain the 








3.4.2. Isotherms and area under the curve of DPPC:POPC. In the case of 
DPPC:POPC, a distinct plateau appears around 45 mN/m. This plateau 
corresponds to the collapse pressure of POPC, thus indicating a rejection of 
material from the surface. However, soon after, the refined isotherm follows a 
steeper slope reaching surface pressure of above 70 mN/m. Once the monolayer 
is expanded the surface pressure starts to plummet until it reaches values of 13 
mN/m and beyond that point the slope becomes more gradual. In the case of 
DPPC:POPC we see smaller hysteresis than DPPC/POPG. Addition of ECN 
shows no change in the compression curve initially. But we do observe a larger 
hysteresis with ECN in the monolayer. Furthermore, we see a large shift in the 
isotherms with the addition of ECN, indicating loss in material. A more 
quantitative approach to identifying material loss will be discussed in the 
subsequent sections. 
The area under the curve for the first cycle of DPPC:POPC control is 
around 3.45. We again see a large drop in the area as the isotherm goes through 
a second cycle of compression and expansion. Finally, after the fifth cycle, the 
value drops to about 3.13. When ECN is added, the first isotherm has an area 
very similar to that of the control. However, we see a greater reduction in the 
area as we go through the remaining cycles of compression/expansion. After the 




3.4.3. Isotherms and area under the curve of DPPC:DPPG. Figure 3 shows 
the Π–A isotherms of DPPC:DPPG (7:3) with and without 1 wt% ECN added to 
the samples. Because the monolayer here comprises of two disaturated 
phospholipids, the surface gets well packed almost immediately after 
compression. The LE phase is short lived and there is a sharp rise in the surface 
pressure with compression. Here, the surface pressure reaches around 70 
mN/m, after which the sample undergoes collapse, with a plateau appearing in 
the isotherm. Once the sample is expanded, the surface pressure drops to zero 
with almost very little change in the area of the trough. Among the four samples 
tested, DPPC:DPPG has the largest hysteresis along with the highest loss in 
material from the surface. This again is expected since the saturated 
components fail to respread after reaching collapse pressure. When ECN is 
added to the samples, there is a shift in the compression curve to higher area of 
trough. However, the shape of the curve is not altered in the presence of ECN, 
i.e., the phase transformations remain the same as that of the control. 
Additionally, we observe a positive influence of the ECN since less material is 
lost from the surface in this case. This disaturated composition shows the highest 
area under the curve for the first cycle at a value of about 3.75. However, in this 
case, much of the material from the surface is lost while undergoing the 









Fig 3. (A) Surface Pressure versus area isotherms for DPPC:DPPG (7:3) without 
(control, red solid line) and with 1 wt % ECN (black solid line). Here again, the samples 
were compressed and expanded five times to understand loss of material from the 
surface. An average of three samples was taken to graph the data. (B) Area under the 
curve as a function of compression/expansion cycle for DPPC:DPPG (7:3) without 
(control, red square) and with 1 wt. %  ECN (black square). In this case, the log-





The fifth cycle seems to have a negligible amount remaining at the surface. Here 
again, we observe an increase in the area of the first cycle compared to the 
control when ECN is added. The log-transformed, integral area reaches a value 
of about 3.8 initially. But like the control, there is a drastic loss in material when 
the sample is compressed/expanded. Further data presented in Figure 5 shows 
improvement in material retention with the introduction of ECN.  
	
3.4.4. Isotherms and area under the curve of DPPC:DPPE. Figure 4 shows 
the Π–A isotherms of DPPC:DPPE (7:3) with and without 1% ECN added to the 
sample. Here too, the monolayer gets well packed upon compression because of 
the presence of two disaturated components. The surface pressure rises with a 
steep slope, rapidly reaching high values. Upon reaching the maximum pressure, 
the isotherm goes through a plateau as the sample collapses. While expanding 
the monolayer, the surface pressure drops sharply till it reaches around 7 mN/m, 
and then the isotherm goes through another plateau to reach near zero values. 
The subsequent cycles move to lower areas of the trough, however, the loss is 
less than that of DPPC:DPPG. The isotherms follow a similar path when 1% ECN 
is added to the sample. A further analysis of the area under the curve provides a 
better understanding of the loss.  
Figure 4B shows the area under the curve for DPPC:DPPE. For the first 
compression/expansion cycle of the control, the area reaches about 3.75. There 





Fig 4. (A) Surface Pressure versus area of the trough isotherms for DPPC:DPPE (7:3) 
without (control, red solid line) and with 1 wt % ECN (black solid line). All samples were 
compressed and expanded five times. The data has been represented as the mean of 3   
samples. (B) Area under the curve as a function of compression/expansion cycle for 
DPPC:DPPE (7:3) without (control, red square) and with 1 wt. %  ECN (black square). 
The log-transformed mean and standard deviation of three samples have been shown in 








Finally, for the fifth cycle, the area reduces to a value of 3.39. With the addition of 
ECN, the first few cycles have similar area under the curve as that of the control. 
However, after the third cycle we start observing deviation from the control.  
Next, we obtained the differences in the area under the curve between the 
control and the samples containing ECN for each cycle such that we can have a 
better understanding of the deviation from the control  once ECN is added.  
3.4.5. Difference in the area under the curve for the samples tested. The 
difference in the integral area under the curve between the control and 1% ECN 
provides us with the impact of ECN on material loss. Positive values for the 
difference suggest the presence of less material at the interface when ECN is 
added, whereas, negative values imply more material is present when ECN is 
added to the sample. Thus, negative values for this graph is indicative of an 
improvement in the sample in terms of material retention. In the case of 
DPPC:POPG, we see mostly positive changes when ECN is added. Only for the 
first cycle, we have a mean value of  – 0.03 mN-m. For the rest of the cycles, the 
deviation yields positive data. In the case of DPPC:POPC, we see positive data 
for all the cycles. However, when ECN is added to the disaturated material, we 
start observing negative values for each cycle. In the case of DPPC:DPPG, we 
see negative values for all the cycles. Therefore, ECN shows a beneficial impact 
on DPPC:DPPG. In the case of DPPC:DPPE, the mean for all the cycles has 




Fig 5. Difference in the area under the curve between control and samples containing 
1% ECN for each compression/expansion isotherm. DPPC:POPG is shown by the red 
bars, DPPC:POPC by blue, DPPC:DPPG by green and DPPC:DPPE by purple. Each 
bar represents the mean of 3 samples. The control data is independent from that of the 
samples containing ECN. Therefore, finding the total variance and subsequently taking 
the square root of the total variance, we obtained the standard deviation of the difference 
for each cycle. Mathematically,        
  
Here, σcontrol is the standard deviation of the control samples, σECN is the standard 
deviation of the samples, which contain ECN, and σtotal is the overall standard deviation 






Fig 6. Effective molecular area and difference in effective molecular area derived by 
fitting Volmer’s equation to Π–A isotherms. (A) One of the parameters of equation 3 is 
the effective molecular area, denoted by ωeff. ωeff as a function of 
compression/expansion cycle was plotted for DPPC:POPG (7:3) control (closed square), 
DPPC:POPG (7:3) with 1% ECN (open square), DPPC:POPC (7:3) control (closed 
circle) and DPPC:POPC (7:3) with 1% ECN (open circle). (B) A difference in ωeff 
between the control and1%ECN has been plotted for DPPC:POPG (7:3) (red square) 
and DPPC:POPC (blue circle). The data has been represented as the mean and 






3.4.6. Effective molecular area for DPPC:POPG and DPPC:POPC. Material 
loss can be characterized by the parameter ωeff. A decrease in ωeff with each 
subsequent cycle of compression/expansion indicates a loss in material. In the 
case of DPPC:POPG control, the area drops from around 58 cm2 to 37 cm2 over 
five compression/expansion cycles. With the addition of ECN to the sample, the 
effective molecular area drops to as low as 33 cm2. In the case of DPPC:POPC 
control, the loss is smaller than that for DPPC:POPG. From around 57 cm2 
initially, ωeff drops to about 48 cm2 over 5 compression/expansion cycles. With 
the addition of ECN to DPPC:POPC the  ωeff for the first cycle is higher than that 
of the control. However, from 65 cm2 at the first cycle, the ωeff drops to about 47 
cm2 after the 5th cycle. At this point, it should be mentioned that the disaturated 
mixtures transform to a condensed monolayer very quickly. For this reason, we 
were not able to model the disaturated systems using Volmer’s equation. As our 
next step, we plotted the change in the effective molecular area between the 
control and 1% ECN for each cycle for DPPC:POPG and DPPC:POPC. 
3.4.7. Change in effective molecular area for DPPC:POPG and DPPC:POPC. 
A difference between the effective molecular areas for the control and the 
samples with 1% ECN was obtained for each cycle. A larger deviation from the 
control suggests loss in material. Initially, more effective area is available for 
DPPC:POPC with 1% ECN than it’s DPPC:POPG counterpart. A positive value 
for POPC suggests strong interaction with ECN. Therefore, charge repulsion may 
be a reason for the negative values in the case of DPPC:POPG. However, from 






Fig 7. Fluorescence micrographs taken after monolayer collapse. (A) DPPC:POPG (7:3) 
control, (B) DPPC:POPC (7:3) control, (C) DPPC:DPPG (7:3) control, (D) DPPC:DPPE 
(7:3) control, (E) DPPC:POPG (7:3) with 1 wt% ECN, (F) DPPC:POPC (7:3) with 1% 
ECN, (G) DPPC:DPPG (7:3) with 1 wt% ECN and (H) DPPC:DPPE (7:3) with 1% ECN. 
The arrows point out folded, reversible, collapse features on the monolayer. The circles 






3.4.8. Fluorescence Micrographs of the samples tested. Figures 7(A) and (E) 
display the monolayer collapse for DPPC:POPG control and with 1% ECN. In the 
case of DPPC:POPG control (A), the monolayer collapses with the formation of 
folded features, which have been pointed out by the arrow. These folded 
structures can be easily spotted in an otherwise dark monolayer. While most of 
the monolayer is extremely packed, the regions where the collapse features exist 
appear as bright streaks, perpendicular to the direction of compression, spanning 
across the width of the micrograph. Fig 7E suggests that these features remain 
intact when ECN is added to our sample. The rest of the image appears dark 
because the monolayer becomes extremely packed once the surface pressure 
reaches high values. Similar to the DPPC:POPG monolayer, the DPPC:DPPG 
control (Fig 7C) collapses with the formation of reversible collapse features. 
Moreover, addition of ECN (Fig 7G) to DPPC:DPPG doesn’t alter the collapse 
mechanism in this case. Furthermore, Fig 7D shows the collapse features for 
DPPC:DPPE control. Here too we observe reversible collapse features, and 
when ECN is added (Fig 7H), the reversible collapse features are still present. 
Figures 7B and 7F on the other hand, shows the collapse features in the case of 
DPPC:POPC control and with 1% ECN. The mechanism of collapse is different in 
the case of DPPC:POPC. Here too we find the monolayer to be packed, and 
therefore, the majority of the monolayer appears dark. However, instead of the 
collapse features that was observed in the case of DPPC:POPG, bright specks 
appear in the monolayer. These specks in the monolayer of DPPC:POPC control 
(7B), have been highlighted by circles. When ECN is added to the sample, the 
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specks appear to increase in number. However, the overall mechanism of 
collapse remains the same for all the samples when 1% ECN is added.  
 
3.5. DISCUSSION 
The present work aims at understanding the impact of ECN on two different 
collapse mechanisms of lung surfactant monolayers. Previous studies have 
focused on the effect of nanomaterial on the surface activity and surface 
morphology of native as well as model lung surfactant monolayers [21, 29, 30]. 
Additionally, Kodama et al., used multiple compression/expansion cycles to 
discuss how particle size, ranging from 20 nm to 1.0 µms, affect the phase 
behavior of lung surfactant monolayers [31]. Multiple compression/expansion 
cycles are relevant for lung surfactants because a loss in the material is 
encountered after each cycle of breathing. Therefore, greater loss in the material 
with the addition of nanomaterial suggests a detrimental impact of the particles 
on the proper functioning of the surfactants. This loss in the material is 
dependent on both the phase behavior as well as the collapse mechanism of the 
lung surfactant monolayers. To the best of our knowledge, previous studies have 
focused on understanding the effect of nanomaterial on the phase behavior of 
lung surfactants. However, it is of paramount importance to thoroughly evaluate 
the impact of nanoparticles on the collapse mechanism of lung surfactants, and 
subsequently, quantify the material loss upon multiple compression/expansion 
cycles. For this purpose, we systematically looked at experiments that would 
identify the influence of negatively charged nanoparticles, namely ECN, on the 
	 95	
collapse behavior of the lung surfactants. The phospholipid combinations, which 
we selected for our study, represent two different mechanisms of collapse. The 
first method of collapse includes the phospholipid mixtures that collapse with the 
formation of reversible features like the ones highlighted by arrows in Fig 6. 
DPPC:POPG (7:3), DPPC:DPPG (7:3) and DPPC:DPPE (7:3) fall under this 
category. The other method includes the phospholipid mixture, DPPC:POPC 
(7:3), which collapses with the formation of irreversible collapse features as can 
be seen in Fig 6B. For neither of the systems, ECN altered the overall 
mechanism of collapse. However, when we looked at multiple cycles of 
compressions and expansions, the behavior of ECN changed depending on the 
lipid tail saturation and charge of the phospholipid mixtures. When DPPC:POPG 
is compared with DPPC:POPC, where the only difference lies in the charge of 
the mixture, POPG being negatively charged, whereas POPC being neutral, we 
observe a greater impact of ECN on POPC than on POPG. This impact has been 
presented in Fig 5, where positive values for the difference in the integral area 
under the curve for each cycle between control and ECN implies a greater loss of 
material. Next, we compared DPPC:POPG with DPPC:DPPG. Thus, the only 
difference here lies in the saturation of the lipid tail group. Interestingly, from Fig 
5 we see that DPPC:DPPG had negative values for the difference in the area 
under the curve. Thus, we see a favorable impact of ECN on saturated 
phospholipid groups. However, we also compared DPPC:DPPG with 
DPPC:DPPE. Here, both the mixtures are saturated, and the only difference lies 
in the charge of the mixture. DPPC:DPPG is negatively charged, whereas 
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DPPC:DPPE is a neutral mixture. Between these two mixtures again, 
DPPC:DPPG shows improved properties when ECN is added. As a result, the 
charge of phospholipid mixture is also vital when considering the impact of 
nanodiamonds on the reversibility. Therefore, our data suggest that the impact of 
ECN on the reversibility of phospholipid monolayers is dependent on both the 
charge of the monolayer as well as the lipid tail saturation. However, it should be 
noted that these changes could only be captured with multiple cycles of 
compressions and expansions. Fluorescence imaging on it’s own or even the first 
cycle of compression/ expansion fail to reveal the subtle changes when ECN 
interacts with phospholipid mixtures. Even though immediate exposure to the 
ECN shows minimal changes in the phase behavior of the monolayer, 
successive cycles point out the loss in the material due to the interaction of the 
nanomaterial with lung surfactants. Thus, a thorough understanding of the 
collapse process coupled with the charge of the monolayer as well as the 
phospholipid saturation is essential to evaluate the effect of the nanoparticles on 
lung surfactants. We will discuss our results in details in the following sections. 
3.5.1. Impact of ECN on the phase behavior and material loss of 
phospholipids from multiple compression/expansion cycles. 
Compression/expansion cycles show that the addition of ECN doesn’t reflect 
changes in the phase behavior for DPPC:POPG. The phase transitions remain 
identical to their control counterpart. However, in the case of DPPC:POPC, we 
see a change in the phase behavior with the addition of ECN. For the control 
curve, we observe a plateau around 45 mN/m initially. As we go on compressing 
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and expanding the monolayer repeatedly, the plateau region shrinks. When ECN 
is added to DPPC:POPC, the plateau region exists for all cycles. This plateau 
signifies the squeeze out of material from the monolayer. Thus, the curves 
indicate a higher loss with the addition of ECN to DPPC:POPC. Additionally, we 
observe a positive influence of the nanodiamonds with DPPC:DPPG, with the 
isotherms shifting towards higher area values. This shift also indicates notable 
insertion of the nanoparticles in the monolayer. To understand material loss in 
further details, we obtained the area under the curve for each cycle. A continual 
loss is seen with the progression of compression/expansion cycles for all 
samples tested. Additionally, we observe that the loss is higher in the case of 
DPPC:POPG control than DPPC:POPC control. However, with the addition of 
ECN, we see a steeper initial decrease in the area under the curve for 
DPPC:POPC. Furthermore, Fig 5 shows that the mean deviation for 
DPPC:POPC is greater than that of DPPC:POPG when ECN is added. 
Therefore, the zwitterionic DPPC:POPC is affected more than the negatively 
charged DPPC:POPG. The role of the saturation of the phospholipid tail was 
tested next. With DPPC:DPPG we see a beneficial impact of ECN. Furthermore, 
the zwitterionic as well as saturated DPPC:DPPE showed little impact with ECN. 
Thus, the charge and saturation both contribute towards the interaction with 
ECN. In our previous report, we had already demonstrated that the morphology 
of the LE-C coexistence phase drastically altered in the case of DPPC:POPC 
with ECN [22], whereas, there was no change when ECN was combined with 
DPPC:POPG. Moreover, the same study also pointed out that the location of 
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insertion of the nanodiamonds into the monolayer depended on the saturation of 
the lipid tail group. Thus, the morphology of the monolayer depends on the 
headgroup charge and lipid tail saturation. From our combined studies, we can 
conclude that alterations in the phase behavior eventually affect material 
preservation. 
3.5.2. Volmer’s equation to further evaluate material loss. Other than the shift 
in the integral area under the curve, the loss in the material can also be 
determined from equations of state that describes the phase transitions in 
isotherms. Kuo et al. used a modified Volmer’s equation of state, represented by 
equation 2, to understand the effect of particle size on SDS-DODAB monolayers 
[27]. The Volmer’s fit accurately describes the LE region of the isotherms and in 
Kuo’s article, a modified Volmer’s fit was shown to be effective in relating the 
total surface area to the surface pressure change in the LE region. Effective 
molecular area, ωeff, was then extracted from the fit, and this parameter is directly 
related to the amount of material present on the surface. Thus, a decrease in the 
value of ωeff when 0.5 µm and 1µm particles were added to the SDS-DODAB 
monolayer suggests a loss in material. For our work, we used this theoretical 
model to understand the impact of ECN on the collapse mechanism of lung 
surfactants. In the case of both the controls, we observe a decrease in the ωeff. 
This reduction is expected because a material loss occurs after every cycle for all 
samples, and the data is supported by the information obtained from the area 
under the curve. Upon the addition of ECN to the lung surfactants, we observe a 
further decrease in the ωeff. However, we see a sharper drop in ωeff in the case of 
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DPPC:POPC than DPPC:POPG. This drop has been highlighted in fig 5B by 
taking the difference between the control and 1%ECN at each cycle. Thus, the 
conclusion drawn from the area under the curve is further corroborated by the 
ωeff data.  Finally, fluorescence microscopy was used to have a thorough 
understanding of the collapse mechanism.  
3.5.3. Fluorescence Imaging of the monolayer to visualize the mechanism 
of collapse. Gopal et al. have shown that DPPC:POPG monolayers, laterally 
compressed under conditions, which are similar to our study, collapses via 
reversible folding mechanism [32]. These reversible folds appear as bright 
streaks perpendicular to the direction of compression, and range from 100 µms 
to about 1 mm in length. These reversible structures unfold when the monolayer 
is expanded, and material reincorporates into the monolayer without notably 
altering the morphology. Our study shows the occurrence of similar collapse 
features in the case of DPPC:POPG. With the addition of ECN, we see the 
monolayer retaining this feature. Bright streaks were again seen spanning across 
the fluorescence micrograph.  Therefore, fluorescence images didn’t detect any 
detrimental impact of the nanoparticle on the DPPC:POPG monolayer. However, 
we wanted to observe the effect on another mode of collapse to have a better 
understanding of the interaction. DPPC:POPC monolayers collapses with the 
formation of vesicles, which appears as bright specks on the monolayer. Large 
vesicles usually end up detaching from the monolayer making the collapse 
irreversible.  This phenomenon has been observed for DPPC:POPG monolayers 
at 37oC [32]. At high temperature, the monolayer shows bright specks that are 
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similar to the ones we observed in the case of DPPC:POPC control at room 
temperature. These bright specks are globular vesicles that usually detach from 
the monolayer. However, it has been suggested that some of the globular 
vesicles do remain attached to the surface and gets reincorporated to the surface 
once the monolayer is expanded. In the case of DPPC:POPC control, the 
formation of the vesicles suggests irreversibility of the monolayer. However, 
further inspection using the area under the curve and equation of state fit 
methods suggest preservation of material in the case of DPPC:POPC. In fact, in 
our study, we observed that more material was preserved with DPPC:POPC than 
with DPPC:POPG. When ECN was added to the DPPC:POPC mixture, more 
vesicles appeared on the trough. Coupled with the theoretical methods, we do 
see an initial loss in material for DPPC:POPC and 1% ECN. Thus, some of the 
vesicles, in this case, fail to get reincorporated to the monolayer. A reason for 
this failure may be due to the size and density of the vesicles. With DPPC:DPPG, 
we observe the material retaining the reversible collapse features with the 
addition of ECN. In fact, area analysis showed a positive impact on the mixture. 
Finally, In the case of DPPC:DPPE control, we see the formation of reversible 
collapse features as well. After ECN is added, the collapse features still appear 
on the monolayer. Therefore, through fluorescence images, we can conclude that 
















Table 2. The table summarizes the impact of ECN on the different phospholipid 
mixtures. The disaturated mixtures have either no effect (DPPC:DPPE) or favorable 
(DPPC:DPPG) effect when ECN is added depending on the charge of the mixture. On 
the other hand, some additional loss was recorded for the unsaturated mixtures. 
However, the most loss on an average was recorded for DPPC:POPC (zwitterionic, 
unsaturated).  
 
We report the impact of ECN on the collapse mechanism of lung surfactant 
mixtures. The chosen components of the phospholipid mixtures focus on the role 
of the lipid headgroup charge, the lipid tail saturation and the subsequent phase 
behavior under compression when interacting with the nanodiamonds. Our data 
suggests that a combination of fluorescence images along with multiple 
compression/expansion cycles and equation of state fit to the isotherms is 
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required to have a better understanding of the monolayer collapse. This in turn is 
crucial to gain knowledge on the toxicity of nanomaterial on lung surfactants. We 
observed that ECN never alters the mode of collapse regardless of the 
phospholipid mixture it encounters. When the charge of the phospholipid 
mixtures is considered keeping the composition mono-unsaturated, the 
zwitterionic component, DPPC:POPC, is the most negatively influenced. 
Negatively charged, mono-unsaturated phospholipids, DPPC:POPG, also show 
some loss when coming in contact with ECN. However, when the saturation of 
the mixture is considered keeping the charge negative, the disaturated 
component, DPPC:DPPG, shows improved properties when ECN is added. 
Here, we observe material preservation with the addition of ECN. Therefore, 
saturated compositions are more favorably affected by ECN than their 
unsaturated counterpart. Finally, when the charge of the mixture is altered 
keeping the composition disaturated, we see that the negatively charged, 
disaturated mixture, DPPC:DPPE, shows very little deviation from control. Thus, 
we can conclude that ECN has either no or has a beneficial impact when it 
encounters completely saturated mixtures. When encountering unsaturated 
components, the negatively charged mixture shows less deviation on the 
average, which in turn suggests that anionic lipids are less prone to have 
adverse effects than the zwitterionic ones. Therefore, the composition of the 
phospholipid mixture plays a valuable role in terms of material retention when 
coming in contact with ECN. From our studies, we conclude that the overall 
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charge of the phospholipid composition, as well as the saturation of the tail 
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Chapter 4: Understanding the Collapse Mechanism of Model Lung 














Lung surfactants are a complex mixture of lipids and proteins that covers 
the liquid lining of the alveoli [1]. The type II epithelial cells of the alveoli produce 
the surfactants, and eventually, the surfactants reach the surface of the liquid 
lining [2]. Other than serving as an innate host defense against pathogens [3, 4], 
the surfactants are responsible for reducing the energy needed for breathing as 
well as stabilizing the alveoli by changing the surface tension as a function of the 
alveolar volume. Low surface tension is necessary while exhaling, failing which, 
results in the collapse of the alveoli [5]. Therefore, lung surfactants ensure proper 
breathing, and an absence or dysfunction leads to fatal diseases [6]. At 
equilibrium, the surface tension is roughly around 20 mN/m in the lungs, whereas 
upon lateral compression, the value of surface tension goes to 0 mN/m. One 
other fundamental characteristic of the surfactant is its ability to adsorb rapidly to 
the surface [7]. Thus, these properties of the surfactants act as the guiding 
parameters when preparing model surfactant mixtures intended for surfactant 
replacement therapy in the case of respiratory diseases. However, as stated 
earlier, the composition of the native surfactants is vast making it challenging to 
come up with simple model mixtures that can mimic the natural surfactants. The 
native lung surfactant is a concoction of approximately 90% lipids and 10% 
proteins [8].  Phospholipids form the majority of the surfactant lipids, and among 
them, phosphatidylcholines are the most abundant component. Around 70-80% 
of the total amounts of the lipids are made up of phosphatidylcholine. 
Furthermore, around 50-70% of these phospholipids are saturated, consisting of 
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dipalmitoylphosphatidylcholine [DPPC] primarily. The anionic 
phosphatidylglycerol makes up about 8% of the surfactants. In addition to these 
components, smaller quantities of phosphatidylserine, phosphatidylinositol, 
phosphatidylethanolamine, lysophosphatidylcholine, and sphingomyelin are also 
found in the surfactants. Moreover, neutral lipids also form a part of the 
surfactant pool. Cholesterol makes up about 2.4 weight% of the total surfactants. 
The remaining 10% of the surfactants comprises of two hydrophilic and two 
hydrophobic surfactant proteins. The hydrophilic proteins, SP-A and SP-D serve 
as a line of defense against inhaled pathogens [3], whereas, the hydrophobic 
proteins, SP-B and SP-C, enhance the functionality of the lung surfactants [9]. 
Each component of the surfactant system plays a specific role, and synthetic 
surfactants are concerned with mimicking the functions and biophysical behavior 
of the overall surfactant system. One crucial biophysical property of the 
surfactants at the interface is their ability to go through reversible collapse. Any 
two-dimensional film at the air/water interface when compressed, undergoes 
changes in phase. At compression values higher than that of the critical 
compression pressure, as in the case of exhalation, the monolayer can no longer 
sustain a film, and instead, yields structures in the third dimension. This 
phenomenon of destabilization of the monolayer is called collapse [10]. 
Furthermore, the mechanism of collapse is vital because it determines the 
reversibility of the monolayer. Reversible Langmuir monolayers are capable of 
rapidly adsorbing back to the interface. The reversibility arises from the fact that 
the monolayers collapse through localized, large amplitude buckling [11]. The 
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buckled areas in the monolayer remain close to the interface, and are capable of 
being readsorbed rapidly. Besides reversible folding through buckling, the 
formation of stacked disks has also been shown to reversibly readsorb to the 
interface upon expansion [12]. Thus, multiple mechanisms have been proposed 
to explain the reversibility of lung surfactants. On the contrary, monolayers, which 
are too fluid, or are too rigid, collapse irreversibly by either solubilization or 
fracture. Therefore, the fluidity of the native surfactant is such that the monolayer 
undergoes collapse via a reversible pathway. This reversibility of the lung 
surfactants is attributed to the surfactant proteins, SP-B and SP-C[13, 14]. The 
behavior of SP-B and SP-C, when interacting with anionic mixtures, has been 
thoroughly studied [14, 15]. These surfactant proteins eliminate the loss of 
material from the surface when interacting with the anionic phospholipid mixture. 
Additionally, multilayered protrusions form when native surfactants are 
compressed beyond the critical surface pressure. It has also been shown through 
atomic force microscopy that the formation of these protrusions depends on the 
concentration of the proteins as well as the phospholipid composition [16]. These 
protrusions are a result of the monolayers undergoing collapse. Therefore, we 
hypothesize that the reversibility of the monolayer is a function of the 
phospholipid mixture under consideration along with their inherent surface 
viscosity.  
The role of phospholipid headgroups was evaluated in our work to 
determine the reversibility of model lung surfactant monolayers. For this purpose, 
two lipid compositions were tested, namely, DPPC:POPG and 
	 113	
DPPC:palmitoyloleoyl phosphatidylcholine [DPPC:POPC]. A synthetic analog of 
SP-B, known as Mini-B was used in this study to evaluate the interaction of the 
lipids with the surfactant protein. Mini-B is a 34 amino acid residue, which is 
based on the sequence of the predicted N and C terminal helices of the native 
SP-B [17, 18]. Mini-B contains a +7 charge, which is the same as that of SP-B. 
Furthermore, similar to SP-B, oxidized Mini-B also forms disulfide bridges that 
connect the two helices. Previously, it has been shown that Mini-B is capable of 
mimicking the biophysical properties of its natural counterpart [19], and thus, it 
was selected for this work. Here, we have used Langmuir-Blodgett [LB] 
technique to prepare the monolayers of the phospholipids along with the proteins 
at the air-water interface. The monolayers were compressed and expanded to 
observe the change in surface pressure. The LB trough was also coupled with 
fluorescence microscopy to visualize the monolayer at the interface. Finally, to 
obtain information on the location of protein insertion, the monolayers were 
transferred to sheets of mica. These transferred films were then analyzed under 
the Atomic Force Microscope to obtain topographical information on a nanolevel. 
 
4.2. MATERIAL AND METHODS 
 
4.2.1. MATERIAL 
 The phospholipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG),  1,2,-
dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG),  and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine (POPS) were purchased from Avanti Polar 
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Lipids, Inc. (Alabaster, Al). The phospholipids were purchased in powdered form. 
Sample solutions were prepared in organic solvents, and were stored at -20 oC to 
avoid any loss of solvent due to evaporation.  The synthetic protein Mini-B, 
prepared via solid phase peptide synthesis as described by A.J. Waring et al. 
[17], was obtained from Biopolymer Core Facility, LA Biomed at Harbor, UCLA 
Medical center, Torrance, California. The fluorescent dye, 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine-triethylammonium salt (TXR-DHPE), was 
purchased from Life Technologies (Invitrogen, Grand Island, NY) in powdered 
form. Additionally, organic solvents, namely acetone, isopropanol, and 
chloroform, were procured from Thermo Fisher Scientific Inc. (Pittsburgh, PA). 
The water used in the experiment as well as in the cleaning process was purified 
to a resistivity of 18.2 MΩ cm with a Direct-Q 3 UV system obtained from EMD 
Millipore (Billerica, MA).  
4.2.3. METHODS 
4.2.3.1. Sample Preparation: Binary lipid mixtures of lipids, DPPC:POPG, 
DPPC:POPC, and DPPC:DPPG were prepared in high performance liquid 
chromatography (HPLC) grade chloroform. A 7:3 weight ratio was selected for all 
the mixtures as the DPPC content is the highest in natural surfactants, and 
model synthetic mixtures contain mostly DPPC. Mini-B solutions were formulated 
in 3:1 mixture of HPLC grade chloroform and methanol. Subsequently, Mini-B 
was added to the model phospholipid mixtures. 
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4.2.3.2. Surface Pressure vs. Mean Molecular Area Isotherm: A Langmuir-
Blodgett trough (Biolin Scientific Inc.) was used to evaluate the biophysical 
properties of the model lung surfactant mixtures. Inside the trough is an area 
bounded by a moveable ribbon. The moveable ribbon is capable of compressing 
and expanding, thereby mimicking the breathing process. The bounded area in 
the trough has a minimum area of 46 cm2 and a maximum area of 166 cm2. The 
difference in area is substantial enough for the compressed monolayer of 
mixtures to reach zero surface tension values. The model mixtures were added 
dropwise with a Hamilton glass syringe on purified water sub-phase. We allowed 
20 minutes for the organic solvent to evaporate before starting the 
compression/expansion cycles. For isotherm experiments, we selected a 
compression rate of 125 cm2/min. The surface pressure was recorded by a 
Whilhelmy plate balance (paper filter) that is connected to a pressure sensor 
device. Experiments were conducted in triplicates. 
4.2.3.3. Fluorescence Imaging: The samples were tagged with TXR-DHPE to 
visualize the monolayer. A Nikon Eclipse Fluorescence Microscope was used to 
monitor the formation of lipid domains at the air-water interface. For imaging, we 
used a slower rate of compression (7 cm2/min). Images were captured at 5 mN/m 
intervals in the two-phase coexistence region, and around collapse pressure with 
a CCD camera (Andor LUCA). Five frames for each image sequence was used, 
and the representative images have been presented in this report. Image J (NIH) 
was then used to analyze each image. Further analysis of the domains was 
carried out using Origin (OriginLab, Northampton, MA).  
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4.2.3.4. Atomic Force Imaging: Due to the difference in charge of the two 
monolayers, the protein inserts itself in different locations. To determine the 
location of insertion of Mini-B in the air/water interface, we obtained high-
resolution microscopy images using an Atomic Force Microscope. For this 
imaging technique, the following steps were employed. The monolayers were 
first compressed to a surface pressure of 20 mN/m, and then transferred to a 
cleaved mica substrate using a home-built inverse Langmuir-Schaffer technique, 
a technique developed by Lee et. al [Langmuir, 1998]. Here, the mica sheet sits 
under the surface while the water is slowly aspirated from the sub-phase. With 
aspiration, the monolayer drops on the mica sheet. Furthermore, since the mica 
sheet is under the surface, the film can be visualized constantly during the entire 
process if the focus is carefully maintained on the interface.  The transferred 
monolayer is then dried in Nitrogen, and the topography of the substrate is 
observed using a Veeco diMultimode V microscope. For imaging, we used 
antimony-doped silicon probes (Bruker Scientific) having a resonance frequency 
of 371 kHz. Also, tapping mode in the air was used for imaging, which has a 
scanning limit of 125 X 125 µm2. Snapshots of the surface were taken at a 
maximum scan rate of 1 µm/s, and a resolution of 512 pixels/line. 
4.3. THEORETICAL ANALYSIS 
4.3.1. Compressibility Modulus: The modulus of elasticity, also called 
compressibility modulus (β), describes the ability of monolayers to store 
	 117	
mechanical energy as stress under a compression force. Mathematically it is 
expressed as:  
 
        … (1) 
Additionally, isothermal compressibility, κ, which is the inverse of β, along with β 
itself are second-order derivatives of the free energy, G, mathematically,  
 
                  … (2) 
A change in the β vs. A graph implies first order phase transition. Moreover, 
higher values of β suggest the formation of condensed well-packed films. The 
development of such condensed films is essential for the proper functioning of 
the lung surfactants. For our experiments, the compressibility modulus was 
obtained from the raw isotherm data by calculating the slope of the isotherm at 
each point. Origin 8.62, with built-in functions for finding derivatives, was used to 
obtain the compressibility modulus. Furthermore, the derivatives of the π-A 
isotherms are often noisy because of the fluctuations in the surface pressure 
readings. Therefore, a five-point Fourier filter, another built-in function of Origin 
8.62, was used to smoothen the data.  
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4.3.2. Area Under the Curve: The hysteresis in the isotherm is an indicator of 
the amount of material present on the surface. Higher value of the area under the 
curve implies the presence of more material at the air/water interface. Origin 8.62 
with a built-in function for integration was used to obtain the integral area under 
the curve for each cycle, and a sample set of three was used to calculate the 
average area under the curve for each cycle.  
4.4. RESULTS 
 
4.4.1. ISOTHERMS: DPPC:POPG with and without Mini-B 
 
Fig 1A represents the surface pressure vs. trough area isotherms of 
DPPC:POPG without Mini-B (control). The sample is added at higher trough 
area, and gradually compressed to the minimum area possible. When 
compressed, DPPC:POPG monolayer goes through changes in phase, which 
appears as changes in slope along the isotherm. This change is a result of the 
rearrangement of the phospholipids in the monolayer film. In this mixture, DPPC 
is the primary component, and because of its ability to pack very tightly, DPPC is 
capable of reaching very high values of surface pressure, which is equivalent to 
reaching very low values of surface tension. The first cycle of the isotherm shows 
how the model mixture reaches high surface pressure as expected. However, 
once the monolayer is expanded, there is loss of phospholipid from the surface of 
the monolayer, and therefore, a hysteresis is seen in the curve, i.e., upon 
expansion, the curve no longer retraces the line for compression. This loss is 
apparent in the subsequent cycles of compression/expansion because of a shift 









Fig 1: (A) Surface pressure vs. area isotherm recorded for DPPC:POPG. Fig 1A 
displays multiple compression/expansion cycles to estimate the loss of material from the 
surface. A constant shift of the isotherm towards the lower area of trough suggests a 
loss in the material. (B) The area under the curve calculated from surface pressure vs. 
area isotherm for DPPC:POPG has been shown in Fig 1B. A drastic drop in the area 
was observed in this case. (C) Surface pressure vs. area isotherm recorded for 
DPPC:POPG with and without Mini-B: The figure shows multiple compression expansion 
for DPPC:POPG without (red solid) and with 1% (black dash) as well as 5% (blue dots) 
Mini-B. With Mini-B, the isotherms were elevated to higher values of surface pressure, 
which indicates the interaction of the protein with the lipids at the surface. Here, a 
comparable shift in the isotherms was observed with the addition of Mini-B. (D) The area 
under the curve calculated from surface pressure vs. area isotherm for DPPC:POPG 
with 1% (black circle), 5% (blue triangle) and without (red square) Mini-B. The addition of 
Mini-B shows reversibility similar to that of the DPPC:POPG control surface.  
 
In the case of DPPC:POPG by itself, we see a formidable loss of material, and a 
substantial shift of the isotherm towards the lower areas. Further analysis of this 
loss is represented in Fig 1B, which depicts the area under the curve for each 
cycle of the isotherm. The first cycle has an area of about 0.35 mN-m, whereas, 
the second cycle shows a considerable drop in the area to 0.14 mN-M. The 
subsequent cycles continue to lose material from the surface. Finally, the fifth 
cycle has an area of 0.05 mN-m. Therefore, from an initial value of 0.35 mN-m, 
the area drops to 0.05 mN-m, which is an 85% reduction of the area from the first 
cycle to the fifth cycle. Even from the second cycle to the fifth cycle, there has 
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been a reduction of about 64% in the area under the curve. Mini-B was then 
added to DPPC:POPG.   
Fig 1C demonstrates multiple cycle isotherms of DPPC:POPG without and 
with two different concentrations of Mini-B added to the phospholipid mixture. 
When Mini-B is added, the first cycle for both 1% and 5% shifts to higher areas of 
the trough. This suggests an interaction of the protein with the phospholipid at 
the air/water interface. As expected, both the mixtures shows promising results 
when it comes to lowering the surface tension. After compression, samples 
containing Mini-B reaches high values of surface pressure, similar to that of the 
control. For all the samples tested, Fig 1D compares the area under the curve for 
each cycle.  It can be observed that the area under the curve remains the same 
for all the samples.  
 
 
4.4.2. ISOTHERM: DPPC:POPC with and without Mini-B 
Fig 2A represents the surface pressure versus tough area isotherms of the 
model mixture DPPC:POPC without Mini-B (control). Here too, the sample is 
added at a higher trough area and gradually compressed to the lowest area 
available. Like DPPC:POPG, DPPC:POPC also goes through changes in phase 
at the surface. Notably, a plateau appears at a surface pressure of about 45 
mN/m. This plateau suggests a distinctive collapse of the POPC component of 
the monolayer, which is known to collapse at surface pressures around 45-50 
mN/m. Collapse of the unsaturated POPC lipids causes the film remaining back 
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at the air/water interface to be DPPC rich. Again, since the primary component is 
DPPC, this model mixture is also capable of reaching high surface pressure 
values. Here, multiple cycles do shift the isotherm to lower trough areas. Further 
analysis with area under the curve, represented by Fig 2B, reveals an area of 
0.25 mN-m. With the second cycle, the value in the area decreases to about 0.15 
mN-m. Finally, after the fifth cycle, DPPC:POPC has an area of 0.1mN-m. Thus, 
DPPC:POPC records a 60% reduction in area under the curve from first cycle to 
the fifth.  
Fig 2C shows the multiple compression/expansion cycles of DPPC:POPC 
without and with Mini-B. At higher trough areas, the isotherms overlaps in the 
case of DPPC:POPC. However, upon compression, the samples containing 1% 
and 5% Mini-B both show improvement in surface activity. Furthermore, while the 
mixture with 1% Mini-B has a similar area under the curve as the control, the 


















Fig 2: (A) Surface pressure vs. area isotherm recorded for DPPC:POPC: The figure 
exhibits multiple cycles of compression and expansion. A constant shift of the isotherm 
towards a lower area of trough suggests a loss in the material. (B) The area under the 
curve for DPPC:POPC: A constant drop in the area was observed for DPPC:POPC 
compression/expansion cycles. However, the reduction in material from the surface is 
less than that of DPPC:POPG represented in Fig 1. (C). Surface pressure vs. area 
isotherm recorded for DPPC:POPC with and without Mini-B. The figure displays 
compression and expansion cycles for DPPC:POPC without (red solid) and with 1% 
(black dash) as well as 5% (blue dots) Mini-B. Again, with Mini-B, the isotherms were 
elevated to higher values of surface pressure, which indicates the interaction of the 
protein with the lipids at the surface. 1% Mini-B had a similar loss to that of the control. 
However, 5% Mini-B showed less reduction of material from the surface. (D) The area 
under the curve calculated for DPPC:POPC without (red square) and with 1% (black 
circle) and 5% (blue triangle) Mini-B. DPPC:POPC with 5% Mini-B shows improvement 
in material retention. In the case of control, there was a 57% reduction in the area under 
the curve, whereas, in the case of DPPC:POPC with 5% Mini-B around 38% reduction in 
the area.  
This improvement is more apparent with the area under the curve analysis as 
can be seen in Fig 2D. Initial areas overlap for both control and 5% Mini-B. 
However, DPPC:POPC with 5% Mini-B has an area of 0.16 mN-m at the fifth 
cycle, whereas, DPPC:POPC control has an area of 0.1 mN-m. Thus a 37% 
difference on the average is seen for the fifth cycle.  Moreover, while our results 
show a shift in the curve and decrease in the area under the curve between the 
first and second cycles, the subsequent cycles overlap for lipid systems 
containing 5 wt. % protein.  
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Fig 3: Compressibility modulus vs. area of the trough for DPPC:POPG without and with 
varying concentrations of Mini-B. (A) The figure displays the compressibility modulus of 
the first compression cycle. The red line indicates DPPC:POPG without Mini-B. The 
dashed line shows the compressibility curve for DPPC:POPG with 1% Mini-B, whereas 
the dotted line represents the compressibility curve for DPPC:POPG with 5% Mini-B. 
Addition of Mini-B lowers the compressibility for the first cycle. (B) The compressibility 
modulus of the fifth cycle of compression has been shown in fig 5B. The compressibility 
modulus remains the same for 1% and control. However, 5% Mini-B shows an increase 




Fig 3A plots the compressibility modulus for the first compression cycle for the 
model DPPC:POPG system. At 150 cm2 we observe a short peak of 45 mN/m for 
the control. Beyond this, there is a sharp rise, and the highest peak at 140 mN/m 
is observed around 87 cm2. With 1% Mini-B, the shorter peak appears at the 
same area of the trough as that of the control. However, there is an increase in 
the compressibility value to 55 mN/m for the 1% Mini-B. The highest peak for 1% 
can be seen around 105 cm2. The peak compressibility, corresponding to 
monolayer collapse, is lower for the 1% Mini-B than that of the control. In the 
case of the 5% Mini-B, the highest peak is again lower than that of the control. 
Fig 3B shows the compressibility modulus for the fifth compression cycle. Here, 
the plot for the 1% Mini-B with DPPC:POPG overlaps with that of the control. The 
peak for both 1% and control is at 110 mN/m. However, for the fifth cycle, the 
peak is around 135 mN/m for the 5% sample.  
 
4.4.4.COMPRESSIBILITY MODULUS: DPPC:POPC with and without Mini-B 
Fig 4A shows the compressibility modulus for the first cycle of DPPC:POPC with 
and without Mini-B. For the control, the first peak of 60 mN/m is observed at 120 
cm2 of the trough area. A second peak of 50 mN/m is seen at 60 cm2. When 1% 
and 5% Mini-B is added to DPPC:POPC, both the peaks are higher than that of 
the control. Fig 4B plots the compressibility modulus of the fifth cycle. Here too, 







Fig 4: Compressibility modulus vs. area of the trough for DPPC:POPC without (red 
solid) and with 1% (black dash) and 5% (blue dots) Mini-B. (A) The compressibility 
modulus of the first compression cycle has been plotted in Fig 4A. Addition of Mini-B to 
DPPC:POPC increases the compressibility for the first cycle. (B). The compressibility 
modulus of the fifth cycle of compression has been shown in fig 5B. The compressibility 
modulus remains the same for 1% and control. However, 5% Mini-B shows an increase 








4.4.5. FLUORESCENCE MICROGRAPHS 
Fig 5(A-F) puts forward the fluorescence micrographs taken at the collapse 
pressure of both DPPC:POPG and DPPC:POPC without and with Mini-B. At 
higher surface pressures, the phospholipid mixtures go through collapse. Fig 5A 
represents the collapse image of DPPC:POPG control. The image is primarily 
dark as the monolayer is tightly packed. However, a bright streak, which is a 
common feature for collapse, runs across the image. The monolayer in the solid 
phase folds along that streak. With the addition of Mini-B, given in Fig 5B and 5C, 
the width of the fold increases. These giant collapses are thought to hold 
phospholipid close to the surface, such that, they can reincorporate within the 
monolayer with expansion. Fig 5D, for DPPC:POPC control, on the contrary, 
collapses with the formation of vesicles, which appears as bright specs instead of 
the bright streaks. Fig 5E and 5F represent the collapse of monolayers 
containing DPPC:POPC with 1% Mini-B and DPPC:POPC with 5% Mini-B. In 
both the cases, the monolayer collapses with the formation of vesicles. Similar to 













Fig 5: Images taken at the collapse pressure for (A) DPPC:POPG (7:3) control, (B) 
DPPC:POPG (7:3) with 1 % Mini-B, (C) DPPC:POPG (7:3) with 5% Mini-B, (D) 
DPPC:POPC (7:3) control, (E) DPPC:POPC (7:3) with 1% Mini-B and (F) DPPC:POPC 
(7:3) with 5% Mini-B. Increasing concentration of Mini-B with DPPC:POPG shows the 
formation of folded collapse features. In the case of DPPC:POPC without or with Mini-B, 
collapse occurs with the formation of vesicles, which appear as bright dots. The scale 








4.4.6. ATOMIC FORCE MICROGRAPHS 
Fig 6(A-D) represents the Atomic force images of the monolayers transferred at 
20 mN/m. At this surface pressure, both DPPC:POPG (Fig 6A) and DPPC:POPC 
(Fig 6C) monolayers are biphasic, i.e., covered by regions containing liquid-
expanded phase as well as liquid-condensed phase. The liquid-condensed 
region is made up of the well-packed DPPC, whereas the liquid-expanded part 
contains the unsaturated phospholipid. In the AFM images, the lighter color 
represents taller features on the monolayer. The uniformly raised region is the 
liquid-condensed part and the increased height results from the alignment of the 
lipid tail. The rest of the monolayer consists of the liquid-expanded region 
containing the unsaturated lipids. When comparing the controls for the two lipid 
systems, we observe the liquid-expanded region of DPPC:POPG monolayer is 
more packed than that of the DPPC:POPC monolayer. Additionally, in the case 
of DPPC:POPG the protein inserts itself in the liquid-expanded region, which is 
observed as the raised feature in fig 6B. However, in the case of DPPC:POPC 
with 5% Mini-B (fig 6D), the protein inserts itself in both the liquid-expanded 











Fig 6: Atomic Force Micrographs taken at 20 mN/m for (A) DPPC:POPG (7:3) control, 
(B) DPPC:POPG 5% Mini-B, (C) DPPC:POPC (7:3) control, and (D) DPPC:POPC 5% 
Mini-B: Here, the height of the monolayer has been indicated by varying shades of color 
with lighter areas representing higher values. The lighter region is the liquid condensed 
domain, which is marked by a sharp boundary. Beyond this boundary lies the liquid 
expanded domain. The lipid here is more scattered containing darker regions in 
between. These darker regions do not contain any material. In the case of DPPC:POPG, 
the liquid expanded region has more lipid than that of DPPC:POPC. In figure (B) and (D) 





Our research has been motivated by the need to evaluate the role of 
phospholipid headgroups while interacting with the synthetic surfactant protein, 
Mini-B. Till date, various compositions of phospholipids have been proposed to 
serve as model lung surfactant mixtures. The most simplistic models have 
contained only a single component of the surfactant phospholipids, namely, 
DPPC [20, 21], or a mixture containing DPPC and surfactant proteins along with 
it [22, 23]. However, such minimalistic models fail to function adequately owing to 
the gross omission of the necessary components of the naturally occurring 
surfactants. Therefore, multiple lipid components are now often introduced to 
mimic the natural lung surfactants, and this increase in complexity is 
accomplished using binary mixtures of phospholipids. The properties of the 
mixtures can then be varied according to the charge and saturation of the 
phospholipids in use. Models containing both saturated phospholipids have been 
occasionally used for mimicking the natural surfactants. Since the negatively 
charged PG lipids form an important part of the native pool, PG lipids have been 
introduced along with DPPC to serve as models. Thus, binary saturated mixtures 
of DPPC:DPPG have been used as model candidates [24-26]. However, almost 
fifty percent of the naturally occurring lung surfactants consist of unsaturated 
lipids. Therefore, entirely saturated mixtures are not capable of mimicking the 
functions of the complex surfactants. On the other hand, mixtures containing 
unsaturated lipids added to the saturated ones form an improved mimic of the 
native surfactants. DPPC:POPG is one such recurrent combination, where 
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POPG incorporates both unsaturation and negative charge [27-31]. However, the 
concentration of PG in the natural mixture is less compared to that of PC. 
Consequently, some studies have focused on preparing model mixtures that are 
entirely composed of the PC headgroup.  Olżyńska et al. studied the structural 
characteristics of the DPPC:POPC monolayers through comparing Langmuir 
experiments with Molecular Dynamics simulations [32]. Additionally, Rose et al., 
also examined the surface properties of different combinations of lipid mixtures, 
which included the potential candidate DPPC:POPC through Molecular 
Dynamics simulation [33]. Ternary mixtures comprising of DPPC:POPC:POPG 
has also been proposed as models for lung surfactants [34]. Thus, different 
phospholipid mixtures have been used alongside surfactant proteins to prepare 
formulations for surfactant replacement therapy. On that account, it has become 
essential to understand the biophysical nature of the interaction of the different 
lipid mixtures with synthetic proteins. So far, the interplay of the surfactant 
proteins with the anionic PG headgroup has been discussed in great details [14, 
35]. Specifically, it has been hypothesized that the formation of reversible 
collapse folds, that are enabled due to the presence of anionic PG lipids, are 
essential for improved reversibility of the material lost from the interface during 
monolayer collapse. Here, we focus on the collapse and reversibility of both the 
anionic, DPPC:POPG and the zwitterionic, DPPC:POPC. The primary aim here 
is to compare the contribution of POPC and POPG. The results from Langmuir 
experiments combined with Fluorescence imaging and Atomic Force Microscopy, 
suggests that the material should not only collapse reversibly but also readsorb 
	 134	
quickly to the interface. The following sub-sections discuss the data in further 
details.   
 
4.5.1. Reversibility of the monolayers through Langmuir Isotherms: 
Interaction with the anionic mixture: Multiple cycles of isotherms were used to 
understand the reversibility of the monolayers. The compression/expansion cycle 
of an entirely reversible monolayer would overlap with every preceding cycle. 
Any deviation to lower areas of the trough indicates irreversibility and thereby, 
loss in the material. The isotherms of DPPC:POPG (Fig 1A), in our study, show 
poor reversibility. This data is similar to the study by Holten-Anderson et al., 
where the third compression/expansion cycle of DPPC:POPG shifts largely to 
lower areas of the trough [31]. Additionally, Holten-Anderson reports on the 
interaction of the peptide KL4, which is a synthetic analog of SP-B, with DPPC 
and POPG at the air-water interface. Addition of KL4, leads to the reversible 
folding of the monolayer along with an increase in the surfactant robustness 
when compressed and expanded repeatedly. KL4 interacts specifically with the 
anionic POPG, and subsequently, induces the reversible folds in the monolayer, 
as can be seen through the fluorescent micrographs. The formation of similar 
reversible folds in the presence of anionic lipids has also been observed with the 
native surfactant protein, SP-B [14]. The synthetic protein Mini-B used in our 
study is a functional fragment of SP-B [18]. Having the same positive net charge 
as that of SP-B, Mini-B is similarly adept at interacting with the negatively 
charged lipid mixtures, thereby, producing the giant reversible folds, which has 
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been reported earlier and represented in Fig 7B and 7C [36]. However, at the 
concentrations (1% and 5%) tested in this study, Mini-B did not show any 
improvement in the reversibility, when compared to that of DPPC:POPG after five 
cycles of compression/expansion (Fig 3B). Furthermore, an improvement in the 
compressibility of the monolayer was only noted for the 5% Mini-B after five 
cycles of compression/expansion.  
4.5.2. Reversibility of the monolayers through Langmuir Isotherms: 
Interaction with the zwitterionic mixture: As discussed earlier, the zwitterionic 
lipids form a significant component of naturally occurring lung surfactants. In the 
case of human surfactants, PC and PG exists at a ratio of 4:1 [37]. However, 
unlike the anionic counterpart [28], the collapse and reversibility of the binary 
monolayers containing both saturated and unsaturated PC have not been tested 
extensively. The isotherms reported in Fig 2A shows that the reversibility of the 
zwitterionic mixture on its own is superior to that of DPPC:POPG. Vesicles in the 
form of bright spots (Fig 7D) were observed under the microscope instead of 
giant folds in the case of DPPC:POPC. The reversibility of the 
compression/expansion cycles of DPPC:POPC indicates that these vesicles 
remain close to the interface, and upon the expansion of the monolayer, the 
vesicles get readsorbed to the surface. Gopal et al. showed the formation of 
budding vesicles when DPPC:POPG went under high compression at 30 oC [28]. 
These vesicles reportedly remained attached to the surface and reincorporated 
at the interface upon expansion. Therefore, it is quite possible that the 
zwitterionic mixture of DPPC:POPC collapses with the formation of budding 
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vesicles. One possible explanation for the rapid readsorption and respreading of 
the material is that the surface viscosity of DPPC:POPC monolayer is lower than 
that of the DPPC:POPG monolayer, which has been shown by Saba Ghazvini in 
her dissertation work [38]. Thus, lower viscosity perhaps makes the zwitterionic 
mixture more reversible than the anionic one. When Mini-B is added to the 
system, a similar route of collapse is seen, where, unlike producing the giant 
folds, Mini-B induces the formation of the budding vesicles. Furthermore, the 
area under the curve suggests that DPPC:POPC with 5% Mini-B is highly 
reversible (Fig 2B). Again, this enhanced reversibility with the addition of the 
protein is possible perhaps due to a quick readsorption and respreading of the 
material at the interface. Additionally, the compressibility modulus also indicates 
an overall improvement in the mechanical properties of the monolayer.   
4.5.3. The topography of monolayers using Atomic Force Micrographs: 
Self-associated lung surfactant proteins, as well as multilayered structures for 
lung surfactants at the air/water interface, have been visualized in the past using 
atomic force microscopy [13, 39, 40]. In the absence of Mini-B, the monolayer is 
primarily flat for both DPPC:POPG and DPPC:POPC. Hane et al. had observed 
the formation of bilayer stacks when SP-C interacted with DPPC/egg PG mixture 
[40]. In the case of just the lipid mixture, the bilayer patches were rarely found 
and were also flatter. However, taller bilayer patches were observed with the 
addition of SP-C in the mixture. In our case, we observe the raised features when 
protein is added to either DPPC:POPG or DPPC:POPC mixtures. For 
DPPC:POPG, we observed fewer number of such features, whereas, a greater 
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number was seen in the case of DPPC:POPC. We speculate that these raised 
features are aggregates of protein that may reincorporate into the monolayer, 
thus making them more reversible. The presence of a greater number of such 
features in the case of the 5% Mini-B along with DPPC:POPC is then an indicator 
of enhanced reversibility of the mixture. Furthermore, the LE region is more 
packed for DPPC:POPG than the DPPC:POPC mixture. The difference in 
packing is probably an effect of the difference in the molar mass of the lipid 
headgroups. PG has a lower molar mass than that of PC, and therefore, packs 
more densely than PC. This contrast in the arrangement of the LE phase of the 
monolayer may also lead to dissimilarity in the reversibility.  
Therefore, when considering the interaction of synthetic proteins with 
model lung surfactant mixtures, we must include the ability of the monolayers to 




Our data addresses the role of lipid headgroup charge when interacting with 
Mini-B in terms of collapse and reversibility. Giant folds are considered as 
markers of the reversibility of lung surfactant monolayers. These giant folds when 
formed with surfactant protein, is believed to hold the collapsed lipids close to the 
surface, such that, upon expansion, the lipids can reincorporate themselves into 
the surface. Thus, the reversible mixtures help with material retention at the 
surface, and this feature is particularly important in the case of Surfactant 
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Replacement Therapy. However, our study shows that the neutral mixture, 
DPPC:POPC, is reversible even without the formation of the giant folds. 
DPPC:POPC along with 5% Mini-B proved to be substantially more reversible 
than the other samples tested in the report. These mixtures collapse via the 
formation of vesicles. But some of these vesicles stay close to the surface and 
upon expansion, reincorporates to the interface. Therefore, the reversibility of the 
sample is dependent on the ability of the surfactants to re-adsorb and re-spread, 
which is in turn, dependent on the viscosity of the material. Lower viscosity of 
DPPC:POPC mixtures allows the vesicles to quickly return to the surface and re-
spread. The location of insertion of the protein also plays a part in modifying the 
viscosity of the mixtures. Thus, while considering the reversibility of phospholipid 
monolayers in the presence of synthetic proteins, the role of surface viscosity 
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5.1.SUMMARY, CONCLUSION & FUTURE DIRECTIONS 
This thesis discusses three primary interactions related to lung surfactant research at the 
air-water interface. These interactions have been presented as three separate chapters. 
5.1.1. Chapter 2: The second chapter categorically scrutinizes the interaction of ECN 
with lung surfactants. Besides being able to lower the surface tension to near zero values, 
material retention is another major property of the surfactants. Thus, the amount of 
surfactants retained at the surface in the presence of nanodiamonds has been made the 
critical focus of this chapter. The major findings include the influence of both lipid head 
group charge and tail saturation on the said properties when interacting with the 
nanodiamonds. Saturated lipid mixtures with an overall negative charge shows a positive 
outcome in terms of the mass retained at the surface when coming in contact with ECN. 
On the other hand, saturated mixture with a net neutral charge has no effect when ECN is 
present in the solution. However, the presence of lipid tail unsaturation has a negative 
outcome. Unsaturation combined with neutral mixture shows the most undesirable result. 
Therefore, we conclude that the presence of saturated, negatively charged lipids may 
prove to be beneficial when preparing formulations for drug delivery with engineered 
carbon nanodiamonds. This thesis primarily deals with binary mixtures coming in contact 
with the nanodiamonds. However, in the future, it might be lucrative to increase the 
complexity by preparing ternary lipid mixtures. Because the native surfactant is a cocktail 
of a variety of lipids and proteins, a ternary mixture may be a better representative of the 
natural surfactants. It would be interesting to observe the dynamics of the lipid-ECN 
interaction in the presence of such complex lipid mixtures. Additionally, surfactant 
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proteins may also be added to possibly counter the effect of nanodiamonds. Therefore, 
since this thesis reveals the importance of the composition of the surfactants when 
interacting with ECN, future studies should include the composition of the mixture as one 
of the key parameters for evaluating the said interaction.  
5.5.2. Chapter 3: The third chapter focuses on the interaction of lipids with the synthetic 
protein Mini-B. Synthetic analogs of native surfactant proteins have been considered for 
the treatment of respiratory diseases. The synthetic alternatives provide an opportunity 
for both an increase in production of the replacement formulations as well as a reduction 
in any undesired impact. However, at the same time, the biophysical behavior of such 
components must closely mimic that of the native constituent. In this chapter too, the 
primary goal is to determine the impact of the composition of the surfactants along with 
Mini-B on material retention. The charge of the mixture plays a role in how the protein 
interacts with the lipids. Furthermore, with the help of Atomic Force Microscopy we 
show that a variation in charge of the lipid mixture alters the location of the protein 
insertion. The location where the protein inserts itself, in turn, may alter the surface 
properties of the monolayer, affecting the reversibility. Future studies should include 
more complex lipid mixtures to assess material retention at the air-water interface.  
5.5.3. Chapter 4: The fourth chapter puts forward the interaction of Mini-B with 
cholesterol. Although cholesterol helps in fluidizing the surfactant mixture, it has been 
associated with diseases. Most commercial replacement surfactants are devoid of 
cholesterol. Thus, it is a disputed component of the native surfactant mixture.  In this 
chapter, we show that Mini-B can counter the deleterious effects of cholesterol. Even 
though we see small quantities of cholesterol having noticeable detrimental effect on the 
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reversible collapse, line tension, and compressibility of the lung surfactants, 1 wt.% to 5 
wt.% of Mini-B is capable of countering the negative impacts. In terms of material 
retention, higher concentration of Mini-B (5 wt.%) with smaller quantities of cholesterol 
(1 wt.%) had the least loss in material compared to other combinations of the two 
components. Therefore, our study indicates that small quantities of cholesterol along with 
the synthetic surfactant protein, Mini-B, may be used in surfactant replacement therapy. 
The fluidizing properties of cholesterol may be beneficial in preparing formulations that 
can easily cover the interface upon inhalation, and at the same time, the presence of 
surfactant protein will ensure that the surfactants are retained at the surface. Future 
objectives should look towards extending these findings to the lung cells for 
understanding the effectiveness of the said formulation.  
	
	
 
